Endocannabinoids and endocannabinoid-related mediators: Targets, metabolism and role in neurological disorders

Progress in Lipid Research

Volumn 62, Issue , 2016, Pages 107-128

  Iannotti, Fabio Arturo ^a   Di Marzo, Vincenzo ^a   Petrosino, Stefania ^a,b  

^a CNR   (Italy)

^b Epitech Group SpA   (Italy)

Author keywords

2 Arachidonoyl glycerol; Anandamide; Inflammation; N acyl ethanolamines; Neurodegeneration; Palmitoylethanolamide

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 1 DEOXY 3 (1,1 DIMETHYLBUTYL) DELTA8 TETRAHYDROCANNABINOL; 2 ARACHIDONOYLGLYCEROL; 4 [4 (1,1 DIMETHYLHEPTYL) 2,6 DIMETHOXYPHENYL] 6,6 DIMETHYLBICYCLO[3.1.1]HEPT 2 EN 2 YLMETHANOL; 4 [BIS(1,3 BENZODIOXOL 5 YL)HYDROXYMETHYL] 1 PIPERIDINECARBOXYLIC ACID 4 NITROPHENYL ESTER; ADENOSINE TRIPHOSPHATE; ANANDAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CAPSAICIN; CAPSAZEPINE; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; DEXANABINOL; ENDOCANNABINOID; G PROTEIN COUPLED RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; N (4 HYDROXYPHENYL)ARACHIDONAMIDE; PALMIDROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOLIPASE C; PROTEIN KINASE B; RIMONABANT; TRANSIENT RECEPTOR POTENTIAL CHANNEL; UNINDEXED DRUG; VANILLOID RECEPTOR 1; VIRODHAMINE; VOLTAGE GATED POTASSIUM CHANNEL; ACYLGLYCEROL; AMIDE; ARACHIDONIC ACID DERIVATIVE; CANNABINOID RECEPTOR; GLYCERYL 2-ARACHIDONATE;

ALZHEIMER DISEASE; BINDING AFFINITY; BIOSYNTHESIS; BRAIN REGION; CELL FATE; CELL FUNCTION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME REGULATION; ENZYME SYNTHESIS; EPILEPSY; HUMAN; HUNTINGTON CHOREA; HYDROLYSIS; MULTIPLE SCLEROSIS; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PHYSIOLOGICAL PROCESS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; REVIEW; ANIMAL; LIPID METABOLISM; METABOLISM;

ANIMALS; ARACHIDONIC ACIDS; ENDOCANNABINOIDS; GLYCERIDES; HUMANS; LIPID METABOLISM; METABOLIC NETWORKS AND PATHWAYS; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; POLYUNSATURATED ALKAMIDES; RECEPTORS, CANNABINOID; RECEPTORS, G-PROTEIN-COUPLED; TRANSIENT RECEPTOR POTENTIAL CHANNELS;

EID: 84963624950     PISSN: 01637827     EISSN: 18732194     Source Type: Journal    
DOI: 10.1016/j.plipres.2016.02.002     Document Type: Review

References (405)

1. Y. Gaoni, and R. Mechoulam Isolation, structure, and partial synthesis of an active constituent of hashish J. Am. Chem. Soc. 86 1964 1646 1647
2. A.C. Howlett The CB1 cannabinoid receptor in the brain Neurobiol. Dis. 5 1998 405 416
3. L.A. Matsuda, S.J. Lolait, M.J. Brownstein, A.C. Young, and T.I. Bonner Structure of a cannabinoid receptor and functional expression of the cloned cDNA Nature 346 1990 561 564
4. S. Munro, K.L. Thomas, and M. Abu-Shaar Molecular characterization of a peripheral receptor for cannabinoids Nature 365 1993 61 65
5. V. Di Marzo, A. Fontana, H. Cadas, S. Schinelli, G. Cimino, J.C. Schwartz, and et al. Formation and inactivation of endogenous cannabinoid anandamide in central neurons Nature 372 1994 686 691
6. W.A. Devane, L. Hanus, A. Breuer, R.G. Pertwee, L.A. Stevenson, G. Griffin, and et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor Science 258 1992 1946 1949
7. R. Mechoulam, S. Ben Shabat, L. Hanus, M. Ligumsky, N.E. Kaiminski, A.R. Schatz, and et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors Biochem. Pharmacol. 50 1995 83 90
8. T. Sugiura, S. Kondo, A. Sukagawa, S. Nakane, A. Shinoda, K. Itoh, and et al. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain Biochem. Biophys. Res. Commun. 215 1995 89 97
9. V. Di Marzo The endocannabinoid system: its general strategy of action, tools for its pharmacological manipulation and potential therapeutic exploitation Pharmacol. Res. 60 2009 77 84
10. S. Petrosino, and V. Di Marzo FAAH and MAGL inhibitors: therapeutic opportunities from regulating endocannabinoid levels Curr. Opin. Investig. Drugs 11 2010 51 62
11. M. Kaczocha, S.T. Glaser, J. Chae, D.A. Brown, and D.G. Deutsch Lipid droplets are novel sites of N-acylethanolamine inactivation by fatty acid amide hydrolase-2 J. Biol. Chem. 285 2010 2796 2806
12. N. Ueda, K. Tsuboi, and T. Uyama N-acylethanolamine metabolism with special reference to N-acylethanolamine-hydrolyzing acid amidase (NAAA) Prog. Lipid Res. 49 2010 299 315
13. S. Petrosino, T. Iuvone, and V. Di Marzo N-palmitoyl-ethanolamine: biochemistry and new therapeutic opportunities Biochimie 92 2010 724 727
14. H.A. Overton, M.C. Fyfe, and C. Reynet GPR119, a novel G protein-coupled receptor target for the treatment of type 2 diabetes and obesity Br. J. Pharmacol. 153 2008 S76 S81
15. G. Godlewski, L. Offertáler, J.A. Wagner, and G. Kunos Receptors for acylethanolamides-GPR55 and GPR119 Prostaglandins Other Lipid Mediat. 89 2009 105 111
16. F. Borrelli, B. Romano, S. Petrosino, E. Pagano, R. Capasso, D. Coppola, and et al. Palmitoylethanolamide, a naturally occurring lipid, is an orally effective intestinal anti-inflammatory agent Br. J. Pharmacol. 172 2015 142 158
17. S.M. Huang, T. Bisogno, T.J. Petros, S.Y. Chang, P.A. Zavitsanos, R.E. Zipkin, and et al. Identification of a new class of molecules, the arachidonyl amino acids, and characterization of one member that inhibits pain J. Biol. Chem. 276 2001 42639 42644
18. G. Milman, Y. Maor, S. Abu-Lafi, M. Horowitz, R. Gallily, S. Batkai, and et al. N-arachidonoyl l-serine, an endocannabinoid-like brain constituent with vasodilatory properties Proc. Natl. Acad. Sci. U. S. A. 103 2006 2428 2433
19. R. Smoum, A. Bar, B. Tan, G. Milman, M. Attar-Namdar, O. Ofek, and et al. Oleoyl serine, an endogenous N-acyl amide, modulates bone remodeling and mass Proc. Natl. Acad. Sci. U. S. A. 107 2010 17710 17715
20. I. Matias, J. Chen, L. De Petrocellis, T. Bisogno, A. Ligresti, F. Fezza, and et al. Prostaglandin ethanolamides (prostamides): in vitro pharmacology and metabolism J. Pharmacol. Exp. Ther. 309 2004 745 757
21. K.R. Kozak, B.C. Crews, J.L. Ray, H.H. Tai, J.D. Morrow, and L.J. Marnett Metabolism of prostaglandin glycerol esters and prostaglandin ethanolamides in vitro and in vivo J. Biol. Chem. 276 2001 36993 36998
22. K.C.M. Verhoeckx, T. Voortman, M.G.J. Balvers, H.F.J. Hendriks, H.M. Wortelboer, and R.F. Witkamp Presence, formation and putative biological activities of N-acyl serotonins, a novel class of fatty-acid derived mediators, in the intestinal tract Biochim. Biophys. Acta 2011 1811 578 586
23. M. Siller, S. Goyal, F.K. Yoshimoto, Y. Xiao, S. Wei, and F.P. Guengerich Oxidation of endogenous N-arachidonoylserotonin by human cytochrome P450 2U1 J. Biol. Chem. 289 2014 10476 10487
24. V. Di Marzo, and J. Wang The endocannabinoidome: the world of endocannabinoids and related mediators 2015 Academic Press 1 187
25. R.G. Pertwee Receptors and channels targeted by synthetic cannabinoid receptor agonists and antagonists Curr. Med. Chem. 17 2010 1360 1381
26. M. Herkenham, A.B. Lynn, M.D. Little, M.R. Johnson, L.S. Melvin, B.R. de Costa, and et al. Cannabinoid receptor localization in brain Proc. Natl. Acad. Sci. U. S. A. 87 1990 1932 1936
27. G. Turu, and L. Hunyady Signal transduction of the CB1 cannabinoid receptor J. Mol. Endocrinol. 44 2010 75 85
28. M.R. Elphick, and M. Egertová The neurobiology and evolution of cannabinoid signalling Philos. Trans. R. Soc. Lond. Ser. B Biol. Sci. 356 2001 381 408
29. J.A. Przybyla, and V.J. Watts Ligand-induced regulation and localization of cannabinoid CB1 and dopamine D2L receptor heterodimers J. Pharmacol. Exp. Ther. 332 2010 710 719
30. S. Ferré, C. Lluís, Z. Justinova, C. Quiroz, M. Orru, G. Navarro, and et al. Adenosine-cannabinoid receptor interactions. implications for striatal function Br. J. Pharmacol. 160 2010 443 453
31. R.J. Ward, J.D. Pediani, and G. Milligan Heteromultimerization of cannabinoid CB(1) receptor and orexin OX(1) receptor generates a unique complex in which both protomers are regulated by orexin A J. Biol. Chem. 286 2011 37414 37428
32. N. Stella Cannabinoid and cannabinoid-like receptors in microglia, astrocytes, and astrocytomas Glia 58 2010 1017 1030
33. J.F. Oliveira da Cruz, L.M. Robin, F. Drago, G. Marsicano, and M. Metna-Laurent Astroglial type-1 cannabinoid receptor (CB1): a new player in the tripartite synapse Neuroscience S0306-4522 15 2015 00434
34. M. Navarrete, and A. Araque Endocannabinoids potentiate synaptic transmission through stimulation of astrocytes Neuron 68 1 2010 113 126
35. T. Gómez del Pulgar, G. Velasco, and M. Guzmán The CB1 cannabinoid receptor is coupled to the activation of protein kinase B/Akt Biochem. J. 347 2000 369 373
36. M.G. Sánchez, L. Ruiz-Llorente, A.M. Sánchez, and I. Díaz-Laviada Activation of phosphoinositide 3-kinase/PKB pathway by CB(1) and CB(2) cannabinoid receptors expressed in prostate PC-3 cells. Involvement in Raf-1 stimulation and NGF induction Cell. Signal. 15 2003 851 859
37. G. Witkowski, R. Rola, and P. Szulczyk Effect of cyclic adenosine monophosphate on the G protein-dependent inward rectifier K(+)-like channel current in medial prefrontal cortex pyramidal neurons J. Physiol. Pharmacol. 63 2012 457 462
38. R.G. Pertwee Pharmacology of cannabinoid CB1 and CB2 receptors Pharmacol. Ther. 74 1997 129 180
39. A.C. Howlett, and S. Mukhopadhyay Cellular signal transduction by anandamide and 2-arachidonoylglycerol Chem. Phys. Lipids 108 2000 53 70
40. J. Mu, S.Y. Zhuang, M.T. Kirby, R.E. Hampson, and S.A. Deadwyler Cannabinoid receptors differentially modulate potassium A and D currents in hippocampal neurons in culture J. Pharmacol. Exp. Ther. 291 1999 893 902
41. R.I. Wilson, and R.A. Nicoll Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses Nature 410 2001 588 592
42. V. Di Marzo, and L. De Petrocellis Why do cannabinoid receptors have more than one endogenous ligand? Philos. Trans. R. Soc. Lond. Ser. B Biol. Sci. 367 2012 3216 3228
43. B.E. Alger Endocannabinoids at the synapse a decade after the dies mirabilis (29 March 2001): what we still do not know J. Physiol. 590 2012 2203 2212
44. R. Talwar, and V.K. Potluri Cannabinoid 1 (CB1) receptor - pharmacology, role in pain and recent developments in emerging CB1 agonists CNS Neurol. Disord. Drug Targets 10 2011 536 544
45. I. Matias, and V. Di Marzo Endocannabinoid synthesis and degradation, and their regulation in the framework of energy balance J. Endocrinol. Investig. 29 2006 15 26
46. F.A. Iannotti, F. Piscitelli, A. Martella, E. Mazzarella, M. Allarà, V. Palmieri, and et al. Analysis of the "endocannabinoidome" in peripheral tissues of obese Zucker rats Prostaglandins Leukot. Essent. Fat. Acids 89 2013 127 135
47. F.A. Iannotti, C. Silvestri, E. Mazzarella, A. Martella, D. Calvigioni, F. Piscitelli, and et al. The endocannabinoid 2-AG controls skeletal muscle cell differentiation via CB1 receptor-dependent inhibition of Kv7 channels Proc. Natl. Acad. Sci. U. S. A. 111 2014 E2472 E2481
48. C. Ravinet Trillou, C. Delgorge, C. Menet, M. Arnone, and P. Soubrié CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity Int. J. Obes. Relat. Metab. Disord. 28 2004 640 648
49. K. Jin, L. Xie, S.H. Kim, S. Parmentier-Batteur, Y. Sun, X.O. Mao, and et al. Defective adult neurogenesis in CB1 cannabinoid receptor knockout mice Mol. Pharmacol. 66 2004 204 208
50. D.G. Demuth, and A. Molleman Cannabinoid signalling Life Sci. 78 2006 549 563
51. B.K. Atwood, and K. Mackie CB2: a cannabinoid receptor with an identity crisis Br. J. Pharmacol. 160 2010 467 479
52. E.S. Onaivi, H. Ishiguro, J.P. Gong, S. Patel, P.A. Meozzi, L. Myers, and et al. Brain neuronal CB2 cannabinoid receptors in drug abuse and depression: from mice to human subjects PLoS One 20 3 2008 e1640
53. E.S. Onaivi, H. Ishiguro, J.P. Gong, S. Patel, P.A. Meozzi, L. Myers, and et al. Functional expression of brain neuronal CB2 cannabinoid receptors are involved in the effects of drugs of abuse and in depression Ann. N. Y. Acad. Sci. 1139 2008 434 449
54. 2 receptors modulate cocaines actions in mice Nat. Neurosci. 14 9 2011 1160 1166
55. I. Matias, and V. Di Marzo Endocannabinoids and the control of energy balance Trends Endocrinol. Metab. 18 2007 27 37
56. R.I. Staiano, S. Loffredo, F. Borriello, F.A. Iannotti, F. Piscitelli, P. Orlando, A. Secondo, F. Granata, M.T. Lepore, A. Fiorelli, G. Varricchi, M. Santini, M. Triggiani, V. Di Marzo, and G. Marone Human lung-resident macrophages express CB1 and CB2 receptors whose activation inhibits the release of angiogenic and lymphangiogenic factors J. Leukoc. Biol. 2015 (jlb.3HI1214-584R. Epub ahead of print)
57. R.G. Pertwee The pharmacology of cannabinoid receptors and their ligands: an overview Int. J. Obes. 30 2006 S13 S18
58. S. Galiègue, S. Mary, J. Marchand, D. Dussossoy, D. Carrière, P. Carayon, and et al. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations Eur. J. Biochem. 232 1995 54 61
59. S. Ständer, M. Schmelz, D. Metze, T. Luger, and R. Rukwied Distribution of cannabinoid receptor 1 (CB1) and 2 (CB2) on sensory nerve fibers and adnexal structures in human skin J. Dermatol. Sci. 38 3 Jun 2005 177 188
60. L. Campora, V. Miragliotta, E. Ricci, L. Cristino, V. Di Marzo, F. Albanese, M. Federica Della Valle, and F. Abramo Cannabinoid receptor type 1 and 2 expression in the skin of healthy dogs and dogs with atopic dermatitis Am. J. Vet. Res. 73 7 Jul 2012 988 995
61. S. Petrosino, L. Cristino, M. Karsak, E. Gaffal, N. Ueda, T. Tüting, and et al. Protective role of palmitoylethanolamide in contact allergic dermatitis Allergy 65 2010 698 711
62. A.A. Izzo Cannabinoids and intestinal motility: welcome to CB2 receptors Br. J. Pharmacol. 142 2004 1201 1202
63. A.A. Izzo, R. Capasso, G. Aviello, F. Borrelli, B. Romano, F. Piscitelli, and et al. Inhibitory effect of cannabichromene, a major non-psychotropic cannabinoid extracted from Cannabis sativa, on inflammation-induced hypermotility in mice Br. J. Pharmacol. 166 2012 1444 1460
64. T.P. Malan Jr., M.M. Ibrahim, J. Lai, T.W. Vanderah, A. Makriyannis, and F. Porreca CB2 cannabinoid receptor agonists: pain relief without psychoactive effects? Curr. Opin. Pharmacol. 3 2003 62 67
65. G.T. Whiteside, G.P. Lee, and K.J. Valenzano The role of the cannabinoid CB2 receptor in pain transmission and therapeutic potential of small molecule CB2 receptor agonists Curr. Med. Chem. 14 2007 917 936
66. M.J. Caterina, M.A. Schumacher, M. Tominaga, T.A. Rosen, J.D. Levine, and D. Julius The capsaicin receptor: a heat-activated ion channel in the pain pathway Nature 389 1997 816 824
67. L. De Petrocellis, and V. Di Marzo Lipids as regulators of the activity of transient receptor potential type V1 (TRPV1) channels Life Sci. 77 2005 1651 1666
68. V. Di Marzo, and L. De Petrocellis Endocannabinoids as regulators of transient receptor potential (TRP) channels: a further opportunity to develop new endocannabinoid-based therapeutic drugs Curr. Med. Chem. 17 2010 1430 1449
69. F.A. Iannotti, C.L. Hill, A. Leo, A. Alhusaini, C. Soubrane, E. Mazzarella, and et al. Nonpsychotropic plant cannabinoids, cannabidivarin (CBDV) and cannabidiol (CBD), activate and desensitize transient receptor potential vanilloid 1 (TRPV1) channels in vitro: potential for the treatment of neuronal hyperexcitability ACS Chem. Neurosci. 5 2014 1131 1141
70. L. De Petrocellis, J.B. Davis, and V. Di Marzo Palmitoylethanolamide enhances anandamide stimulation of human vanilloid VR1 receptors FEBS Lett. 506 2001 253 256
71. L. De Petrocellis, C.J. Chu, A.S. Moriello, J.C. Kellner, J.M. Walker, and V. Di Marzo Actions of two naturally occurring saturated N-acyldopamines on transient receptor potential vanilloid 1 (TRPV1) channels Br. J. Pharmacol. 143 2004 251 256
72. L. De Petrocellis, V. Vellani, A. Schiano-Moriello, P. Marini, P.C. Magherini, P. Orlando, and et al. Plant-derived cannabinoids modulate the activity of transient receptor potential channels of ankyrin type-1 and melastatin type-8 J. Pharmacol. Exp. Ther. 325 2008 1007 1015
73. P. Ambrosino, M.V. Soldovieri, C. Russo, and M. Taglialatela Activation and desensitization of TRPV1 channels in sensory neurons by the PPARα agonist palmitoylethanolamide Br. J. Pharmacol. 168 2013 1430 1444
74. P. Ambrosino, M.V. Soldovieri, M. De Maria, C. Russo, and M. Taglialatela Functional and biochemical interaction between PPARα receptors and TRPV1 channels: potential role in PPARα agonists-mediated analgesia Pharmacol. Res. 87 2014 113 122
75. 2 + influx via TRPV1 channels EMBO J. 24 2005 3517 3518
76. P. Cesare, L.V. Dekker, A. Sardini, P.J. Parker, and P.A. McNaughton Specific involvement of PKC-epsilon in sensitization of the neuronal response to painful heat Neuron 23 1999 617 624
77. I. Nagy, D. Friston, J.S. Valente, J.V. Torres Perez, and A.P. Andreou Pharmacology of the capsaicin receptor, transient receptor potential vanilloid type-1 ion channel Prog. Drug Res. 68 2014 39 76
78. D. Julius TRP channels and pain Annu. Rev. Cell Dev. Biol. 29 2013 355 384
79. B. Nilius, F. Mahieu, Y. Karashima, and T. Voets Regulation of TRP channels: a voltage-lipid connection Biochem. Soc. Trans. 35 2007 105 108
80. D.N. Cortright, and A. Szallasi Biochemical pharmacology of the vanilloid receptor TRPV1. An update Eur. J. Biochem. 271 2004 1814 1819
81. R. Planells-Cases, N. Garcìa-Sanz, C. Morenilla-Palao, and A. Ferrer-Montiel Functional aspects and mechanisms of TRPV1 involvement in neurogenic inflammation that leads to thermal hyperalgesia Pflugers Arch. 451 2005 151 159
82. S. Mandadi, T. Tominaga, M. Numazaki, N. Murayama, N. Saito, P.J. Armati, and et al. Increased sensitivity of desensitized TRPV1 by PMA occurs through PKCepsilon-mediated phosphorylation at S800 Pain 123 2006 106 116
83. J.D. Brederson, P.R. Kym, and A. Szallasi Targeting TRP channels for pain relief Eur. J. Pharmacol. 716 2013 61 76
84. E. Iwaoka, S. Wang, N. Matsuyoshi, Y. Kogure, S. Aoki, S. Yamamoto, and et al. Evodiamine suppresses capsaicin-induced thermal hyperalgesia through activation and subsequent desensitization of the transient receptor potential V1 channels J. Nat. Med. 2015 (Epub ahead of print)
85. J.G. Edwards TRPV1 in the central nervous system: synaptic plasticity, function, and pharmacological implications Prog. Drug Res. 68 2014 77 104
86. L. Cristino, L. de Petrocellis, G. Pryce, D. Baker, V. Guglielmotti, and V. Di Marzo Immunohistochemical localization of cannabinoid type 1 and vanilloid transient receptor potential vanilloid type 1 receptors in the mouse brain Neuroscience 139 2006 1405 1415
87. F. Mori, M. Ribolsi, H. Kusayanagi, F. Monteleone, V. Mantovani, F. Buttari, and et al. TRPV1 channels regulate cortical excitability in humans J. Neurosci. 32 2012 873 879
88. L.A. Chahl TRP channels and psychiatric disorders Adv. Exp. Med. Biol. 704 2011 987 1009
89. K. Starowicz, L. Cristino, and V. Di Marzo TRPV1 receptors in the central nervous system: potential for previously unforeseen therapeutic applications Curr. Pharm. Des. 14 2008 42 54
90. Y.A. Blednov, and R.A. Harris Deletion of vanilloid receptor (TRPV1) in mice alters behavioral effects of ethanol Neuropharmacology 56 2009 814 820
91. D.A. Ryskamp, S. Redmon, A.O. Jo, and D. Križaj TRPV1 and endocannabinoids: emerging molecular signals that modulate mammalian vision Cell 3 2014 914 938
92. S. Oka, K. Nakajima, A. Yamashita, S. Kishimoto, and T. Sugiura Identification of GPR55 as a lysophosphatidylinositol receptor Biochem. Biophys. Res. Commun. 362 2007 928 934
93. 2 + signaling and NFAT activation FASEB J. 23 2009 183 193
94. H. Sharir, L. Console-Bram, C. Mundy, S.N. Popoff, A. Kapur, and M.E. Abood The endocannabinoids anandamide and virodhamine modulate the activity of the candidate cannabinoid receptor GPR55 J. NeuroImmune Pharmacol. 7 2012 856 865
95. R.G. Pertwee GPR55: a new member of the cannabinoid receptor clan? Br. J. Pharmacol. 152 2007 984 986
96. J. Kargl, N. Balenga, G.P. Parzmair, A.J. Brown, A. Heinemann, and M. Waldhoer The cannabinoid receptor CB1 modulates the signaling properties of the lysophosphatidylinositol receptor GPR55 J. Biol. Chem. 287 2012 44234 44248
97. E. Martínez-Pinilla, I. Reyes-Resina, A. Oñatibia-Astibia, M. Zamarbide, A. Ricobaraza, G. Navarro, and et al. CB1 and GPR55 receptors are co-expressed and form heteromers in rat and monkey striatum Exp. Neurol. 261 2014 44 52
98. C.S. Wu, H. Chen, H. Sun, J. Zhu, C.P. Jew, J. Wager-Miller, and et al. GPR55, a G-protein coupled receptor for lysophosphatidylinositol, plays a role in motor coordination PLoS One 8 2013 e60314
99. E. Ryberg, N. Larsson, S. Sjögren, S. Hjorth, N.O. Hermansson, J. Leonova, and et al. The orphan receptor GPR55 is a novel cannabinoid receptor Br. J. Pharmacol. 152 2007 1092 1101
100. L.S. Whyte, E. Ryberg, N.A. Sims, S.A. Ridge, K. Mackie, P.J. Greasley, and et al. The putative cannabinoid receptor GPR55 affects osteoclast function in vitro and bone mass in vivo Proc. Natl. Acad. Sci. U. S. A. 106 2009 16511 16516
101. J.M. Moreno-Navarrete, V. Catalán, L. Whyte, A. Díaz-Arteaga, R. Vázquez-Martínez, F. Rotellar, and et al. The l-α-lysophosphatidylinositol/GPR55 system and its potential role in human obesity Diabetes 61 2012 281 291
102. C.S. Wu, H. Chen, H. Sun, J. Zhu, C.P. Jew, J. Wager-Miller, and et al. GPR55, a G-protein coupled receptor for lysophosphatidylinositol, plays a role in motor coordination PLoS One 8 4 2013 e60314
103. G. Velasco, A. Carracedo, C. Blázquez, M. Lorente, T. Aguado, A. Haro, C. Sánchez, I. Galve-Roperh, and M. Guzmán Cannabinoids and gliomas Mol. Neurobiol. 36 1 2007 60 67
104. M. Guzmán Cannabinoids: potential anticancer agents Nat. Rev. Cancer 3 10 2003 745 755
105. M. Guzmán, C. Sánchez, and I. Galve-Roperh Control of the cell survival/death decision by cannabinoids J. Mol. Med. (Berl.) 78 11 2001 613 625
106. R. Piñeiro, T. Maffucci, and M. Falasca The putative cannabinoid receptor GPR55 defines a novel autocrine loop in cancer cell proliferation Oncogene 30 2 Jan 13 2011 142 152
107. G. Hu, G. Ren, and Y. Shi The putative cannabinoid receptor GPR55 promotes cancer cell proliferation Oncogene 30 2 2011 139 141
108. V. Di Marzo Endocannabinoid signaling in the brain: biosynthetic mechanisms in the limelight Nat. Neurosci. 14 2011 9 15
109. G.G. Muccioli Endocannabinoid biosynthesis and inactivation, from simple to complex Drug Discov. Today 15 11/12 2010
110. G.M. Simon, and B.F. Cravatt Characterization of mice lacking candidate N-acyl ethanolamine biosynthetic enzymes provides evidence for multiple pathways that contribute to endocannabinoid production in vivo Mol. BioSyst. 6 2010 1411 1418
111. T. Bisogno, F. Howell, G. Williams, A. Minassi, M.G. Cascio, A. Ligresti, and et al. Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain J. Cell Biol. 163 2003 463 468
112. Y. Gao, D.V. Vasilyev, M.B. Goncalves, F.V. Howell, C. Hobbs, M. Reisenberg, and et al. Loss of retrograde endocannabinoid signaling and reduced adult neurogenesis in diacylglycerol lipase knock-out mice J. Neurosci. 30 2010 2017 2024
113. A. Tanimura, M. Yamazaki, Y. Hashimotodani, M. Uchigashima, S. Kawata, M. Abe, and et al. The endocannabinoid 2-arachidonoylglycerol produced by diacylglycerol lipase alpha mediates retrograde suppression of synaptic transmission Neuron 65 2010 320 327
114. 2 + dependency for triggering retrograde endocannabinoid signal Neuron 45 2005 257 268
115. 2 +-assisted metabotropic glutamate receptor subtype 1 to phospholipase Cbeta4 signaling cascade in the cerebellum J. Neurosci. 25 2005 6826 6835
116. T. Bisogno, I. Delton-Vandenbroucke, A. Milone, M. Lagarde, and V. Di Marzo Biosynthesis and inactivation of N-arachidonoylethanolamine (anandamide) and N docosahexaenoylethanolamine in bovine retina Arch. Biochem. Biophys. 370 1999 300 307
117. N. Ueda Endocannabinoid hydrolases Prostaglandins Other Lipid Mediat. 68-69 2002 521 534
118. G. Labar, C. Bauvois, F. Borel, J.-L. Ferrer, J. Wouters, and D.M. Lambert Crystal structure of the human monoacylglycerol lipase, a key actor in endocannabinoid signaling Chembiochem 11 2010 218 227
119. U. Taschler, F.P. Radner, C. Heier, R. Schreiber, M. Schweiger, G. Schoiswohl, and et al. Monoglyceride lipase deficiency in mice impairs lipolysis and attenuates diet-induced insulin resistance J. Biol. Chem. 286 2010 17467 17477
120. B.F. Cravatt, and A.H. Lichtman Fatty acid amide hydrolase: an emerging therapeutic target in the endocannabinoid system Curr. Opin. Chem. Biol. 7 2003 469 475
121. B.O. Wei, T.S. Mikkelsen, M.K. McKinney, E.S. Lander, and B.F. Cravatt A second fatty acid amide hydrolase with variable distribution among placental mammals J. Biol. Chem. 281 2006 36569 36578
122. A. Saghatelian, S.A. Trauger, E.J. Want, E.G. Hawkins, G. Siuzdak, and B.F. Cravatt Assignment of endogenous substrates to enzymes by global metabolite profiling Biochemistry 43 2004 14332 14339
123. A. Saghatelian, M.K. McKinney, M. Bandell, A. Patapoutian, and B.F. Cravatt A FAAH-regulated class of N-acyl taurines that activates TRP ion channels Biochemistry 45 2006 9007 9015
124. S.K. Goparaju, N. Ueda, H. Yamaguchi, and S. Yamamoto Anandamide amidohydrolase reacting with 2-arachidonoylglycerol, another cannabinoid receptor ligand FEBS Lett. 422 1998 69 73
125. V. Di Marzo, T. Bisogno, T. Sugiura, D. Melck, and L. De Petrocellis The novel endogenous cannabinoid 2-arachidonoylglycerol is inactivated by neuronal- and basophil-like cells: connections with anandamide Biochem. J. 331 1998 15 19
126. S. Maione, T. Bisogno, V. de Novellis, E. Palazzo, L. Cristino, M. Valenti, and et al. Elevation of endocannabinoid levels in the ventrolateral periaqueductal grey through inhibition of fatty acid amide hydrolase affects descending nociceptive pathways via both cannabinoid receptor type 1 and transient receptor potential vanilloid type-1 receptors J. Pharmacol. Exp. Ther. 316 2006 969 982
127. J.L. Blankman, G.M. Simon, and B.F. Cravatt A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol Chem. Biol. 14 2007 1347 1356
128. M. Mor, S. Rivara, A. Lodola, P.V. Plazzi, G. Tarzia, A. Duranti, and et al. Cyclohexylcarbamic acid 3′- or 4′-substituted biphenyl-3-yl esters as fatty acid amide hydrolase inhibitors: synthesis, quantitative structure-activity relationships, and molecular modeling studies J. Med. Chem. 47 2004 4998 5008
129. A.H. Lichtman, D. Leung, C.C. Shelton, A. Saghatelian, C. Hardouin, D.L. Boger, and et al. Reversible inhibitors of fatty acid amide hydrolase that promote analgesia: evidence for an unprecedented combination of potency and selectivity J. Pharmacol. Exp. Ther. 311 2004 441 448
130. K. Ahn, D.S. Johnson, M. Mileni, D. Beidler, J.Z. Long, M.K. McKinney, and et al. Discovery and characterization of a highly selective FAAH inhibitor that reduces inflammatory pain Chem. Biol. 16 2009 411 420
131. K. Ahn, S.E. Smith, M.B. Liimatta, D. Beidler, N. Sadagopan, D.T. Dudley, and et al. Mechanistic and pharmacological characterization of PF-04457845: a highly potent and selective fatty acid amide hydrolase inhibitor that reduces inflammatory and noninflammatory pain J. Pharmacol. Exp. Ther. 338 2011 114 124
132. A.R. King, A. Duranti, A. Tontini, S. Rivara, A. Rosengarth, J.R. Clapper, and et al. URB602 inhibits monoacylglycerol lipase and selectively blocks 2-arachidonoylglycerol degradation in intact brain slices Chem. Biol. 14 2007 1357 1365
133. G.G. Muccioli, G. Labar, and D.M. Lambert CAY10499, a novel monoglyceride lipase inhibitor evidenced by an expeditious MGL assay Chembiochem 9 2008 2704 2710
134. T. Bisogno, G. Ortar, S. Petrosino, E. Morera, E. Palazzo, M. Nalli, S. Maione, V. Di Marzo, and Endocannabinoid Research Group Development of a potent inhibitor of 2-arachidonoylglycerol hydrolysis with antinociceptive activity in vivo Biochim. Biophys. Acta 2009 1791 53 60
135. J.Z. Long, W. Li, L. Booker, J.J. Burston, S.G. Kinsey, J.E. Schlosburg, and et al. Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects Nat. Chem. Biol. 5 2009 37 44
136. J.W. Chang, M.J. Niphakis, K.M. Lum, A.B. Cognetta III, C. Wang, M.L. Matthews, and et al. Highly selective inhibitors of monoacylglycerol lipase bearing a reactive group that is bioisosteric with endocannabinoid substrates Chem. Biol. 19 2012 579 588
137. S. Kathuria, S. Gaetani, D. Fegley, F. Valiño, A. Duranti, A. Tontini, and et al. Modulation of anxiety through blockade of anandamide hydrolysis Nat. Med. 9 2003 76 81
138. R.L. Suplita II, J.N. Farthing, T. Gutierrez, and A.G. Hohmann Inhibition of fatty-acid amide hydrolase enhances cannabinoid stress-induced analgesia: sites of action in the dorsolateral periaqueductal gray and rostral ventromedial medulla Neuropharmacology 49 2005 1201 1209
139. S. Ghosh, L.E. Wise, Y. Chen, R. Gujjar, A. Mahadevan, B.F. Cravatt, and et al. The monoacylglycerol lipase inhibitor JZL184 suppresses inflammatory pain in the mouse carrageenan model Life Sci. 92 2013 498 505
140. D.K. Nomura, C.S. Hudak, A.M. Ward, J.J. Burston, R.S. Issa, K.J. Fisher, and et al. Monoacylglycerol lipase regulates 2-arachidonoylglycerol action and arachidonic acid levels Bioorg. Med. Chem. Lett. 18 2008 5875 5878
141. R. Imperatore, G. Morello, L. Luongo, U. Taschler, R. Romano, D. De Gregorio, and et al. Genetic deletion of monoacylglycerol lipase leads to impaired cannabinoid receptor CB1 R signaling and anxiety-like behavior J. Neurochem. 135 4 2015 799 813
142. -/- animals Life Sci. 138 Oct 1 2015 52 56
143. 2 receptors Br. J. Pharmacol. 166 4 Jun 2012 1474 1489
144. B.N. Okine, L.M. Norris, S. Woodhams, J. Burston, A. Patel, S.P. Alexander, D.A. Barrett, D.A. Kendall, A.J. Bennett, and V. Chapman Lack of effect of chronic pre-treatment with the FAAH inhibitor URB597 on inflammatory pain behaviour: evidence for plastic changes in the endocannabinoid system Br. J. Pharmacol. 167 3 Oct 2012 627 640
145. V. Di Marzo Targeting the endocannabinoid system: to enhance or reduce? Nat. Rev. Drug Discov. 7 5 2008 438 455
146. H. Kanoh, T. Iwata, T. Ono, and T. Suzuki Immunological characterization of sn-1,2-diacylglycerol and sn-2-monoacylglycerol kinase from pig brain J. Biol. Chem. 261 1986 5597 5602
147. R.A. Coleman, and E.B. Haynes Monoacylglycerol acyltransferase: evidence that the activities from rat intestine and suckling liver are tissue-specific isoenzymes J. Biol. Chem. 261 1986 224 228
148. K.R. Kozak, R.A. Gupta, J.S. Moody, C. Ji, W.E. Boeglin, R.N. DuBois, and et al. 15-Lipoxygenase metabolism of 2-arachidonylglycerol. Generation of a peroxisome proliferator-activated receptor alpha agonist J. Biol. Chem. 277 2002 23278 23286
149. C.A. Rouzer, and L.J. Marnett Non-redundant functions of cyclooxygenases: oxygenation of endocannabinoids J. Biol. Chem. 283 2008 8065 8069
150. S. Zelasko, W.R. Arnold, and A. Das Endocannabinoid metabolism by cytochrome P450 monooxygenases Prostaglandins Other Lipid Mediat. 116-117 2015 112 123
151. D.R. McDougle, A. Kambalyal, D.D. Meling, and A. Das Endocannabinoids anandamide and 2-arachidonoylglycerol are substrates for human CYP2J2 epoxygenase J. Pharmacol. Exp. Ther. 351 2014 616 627
152. S. Nicolussi, and J. Gertsch Endocannabinoid transport revisited Vitam. Horm. 98 2015 441 485
153. M.J. McFarland, and E.L. Barker Anandamide transport Pharmacol. Ther. 104 2 2004 117 135
154. M.J. McFarland, T.K. Bardell, M.L. Yates, E.A. Placzek, and E.L. Barker RNA interference-mediated knockdown of dynamin 2 reduces endocannabinoid uptake into neuronal dCAD cells Mol. Pharmacol. 74 1 Jul 2008 101 108
155. L. Aloe, A. Leon, and R. Levi-Montalcini A proposed autacoid mechanism controlling mastocyte behaviour Agents Actions 39 1993 145 147
156. G. Re, R. Barbero, A. Miolo, and V. Di Marzo Palmitoylethanolamide, endocannabinoids and related cannabimimetic compounds in protection against tissue inflammation and pain: potential use in companion animals Vet. J. 173 2007 21 30
157. E. Esposito, and S. Cuzzocrea Palmitoylethanolamide in homeostatic and traumatic central nervous system injuries CNS Neurol. Disord. Drug Targets 12 2013 55 61
158. G. Mattace Raso, R. Russo, A. Calignano, and R. Meli Palmitoylethanolamide in CNS health and disease Pharmacol. Res. 86 2014 32 41
159. E. Esposito, and S. Cuzzocrea Palmitoylethanolamide is a new possible pharmacological treatment for the inflammation associated with trauma Mini-Rev. Med. Chem. 13 2 2013 237 255
160. A.F. Coburn, C.E. Graham, and J. Haninger The effect of egg yolk in diets on anaphylactic arthritis (passive Arthus phenomenon) in the guinea pig J. Exp. Med. 100 1954 425 435
161. F.A. Kuehl, T.A. Jacob, O.H. Ganley, R.E. Ormond, and M.A.P. Meisinger The identification of N-(2-hydroxyethyl)-palmitamide as a naturally occurring anti-inflammatory agent J. Am. Chem. Soc. 79 1957 5577 5578
162. O.H. Ganley, O.E. Graessle, and H.J. Robinson Anti-inflammatory activity on compounds obtained from egg yolk, peanut oil, and soybean lecithin J. Lab. Clin. Med. 51 1958 709 714
163. N.R. Bachur, K. Masek, K.L. Melmon, and S. Udenfriend Fatty acid amides of ethanolamine in mammalian tissues J. Biol. Chem. 240 1965 1019 1024
164. D.E. Epps, P.C. Schmid, V. Natarajan, and H.H. Schmid N-acylethanolamine accumulation in infarcted myocardium Biochem. Biophys. Res. Commun. 90 1979 628 633
165. E.V. Berdyshev, P.C. Schmid, Z. Dong, and H.H. Schmid Stress-induced generation of N-acylethanolamines in mouse epidermal JB6 P + cells Biochem. J. 2 2000 369 374
166. D. De Filippis, A. DAmico, M. Cipriano, S. Petrosino, P. Orlando, V. Di Marzo, and et al. Levels of endocannabinoids and palmitoylethanolamide and their pharmacological manipulation in chronic granulomatous inflammation in rats Pharmacol. Res. 61 2010 321 328
167. F. Abramo, L. Campora, F. Albanese, M.F. della Valle, L. Cristino, S. Petrosino, and et al. Increased levels of palmitoylethanolamide and other bioactive lipid mediators and enhanced local mast cell proliferation in canine atopic dermatitis BMC Vet. Res. 10 2014 21
168. D. Baker, G. Pryce, J.L. Croxford, P. Brown, R.G. Pertwee, A. Makriyannis, and et al. Endocannabinoids control spasticity in a multiple sclerosis model FASEB J. 15 2001 300 302
169. S. Petrosino, E. Palazzo, V. de Novellis, T. Bisogno, F. Rossi, S. Maione, and et al. Changes in spinal and supraspinal endocannabinoid levels in neuropathic rats Neuropharmacology 52 2007 415 422
170. R. Capasso, A.A. Izzo, F. Fezza, A. Pinto, F. Capasso, N. Mascolo, and et al. Inhibitory effect of palmitoylethanolamide on gastrointestinal motility in mice Br. J. Pharmacol. 134 2001 945 950
171. G. DArgenio, S. Petrosino, C. Gianfrani, M. Valenti, G. Scaglione, I. Grandone, and et al. Overactivity of the intestinal endocannabinoid system in celiac disease and in methotrexate-treated rats J. Mol. Med. (Berl.) 85 2007 523 530
172. A.A. Izzo, G. Aviello, S. Petrosino, P. Orlando, G. Marsicano, B. Lutz, and et al. Increased endocannabinoid levels reduce the development of precancerous lesions in the mouse colon J. Mol. Med. (Berl.) 86 2008 89 98
173. J. Chen, I. Matias, T. Dinh, T. Lu, S. Venezia, A. Nieves, and et al. Finding of endocannabinoids in human eye tissues: implications for glaucoma Biochem. Biophys. Res. Commun. 330 2005 1062 1067
174. I. Matias, J.W. Wang, A.S. Moriello, A. Nieves, D.F. Woodward, and V. Di Marzo Changes in endocannabinoid and palmitoylethanolamide levels in eye tissues of patients with diabetic retinopathy and age-related macular degeneration Prostaglandins Leukot. Essent. Fat. Acids 75 2006 413 418
175. G. Annuzzi, F. Piscitelli, L. Di Marino, L. Patti, R. Giacco, G. Costabile, and et al. Differential alterations of the concentrations of endocannabinoids and related lipids in the subcutaneous adipose tissue of obese diabetic patients Lipids Health Dis. 9 2010 43
176. A. Giuffrida, and D. Piomelli Isotope dilution GC/MS determination of anandamide and other fatty acylethanolamides in rat blood plasma FEBS Lett. 422 1998 373 376
177. D. Schreiber, S. Harlfinger, B.M. Nolden, C.W. Gerth, U. Jaehde, E. Schömig, and et al. Determination of anandamide and other fatty acyl ethanolamides in human serum by electrospray tandem mass spectrometry Anal. Biochem. 361 2007 162 168
178. M.G. Balvers, K.C. Verhoeckx, and R.F. Witkamp Development and validation of a quantitative method for the determination of 12 endocannabinoids and related compounds in human plasma using liquid chromatography-tandem mass spectrometry J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 877 2009 1583 1590
179. A. Franklin, S. Parmentier-Batteur, L. Walter, D.A. Greenberg, and N. Stella Palmitoylethanolamide increases after focal cerebral ischemia and potentiates microglial cell motility J. Neurosci. 23 2003 7767 7775
180. E. Murillo-Rodriguez, F. Désarnaud, and O. Prospéro-García Diurnal variation of arachidonoylethanolamine, palmitoylethanolamide and oleoylethanolamide in the brain of the rat Life Sci. 79 2006 30 37
181. C. Scuderi, G. Esposito, A. Blasio, M. Valenza, P. Arietti, L. Steardo, and et al. Palmitoylethanolamide counteracts reactive astrogliosis induced by β-amyloid peptide J. Cell. Mol. Med. 15 2011 2664 2674
182. N. Stella, and D. Piomelli Receptor-dependent formation of endogenous cannabinoids in cortical neurons Eur. J. Pharmacol. 425 2001 189 196
183. L. Walter, A. Franklin, A. Witting, T. Moller, and N. Stella Astrocytes in culture produce anandamide and other acylethanolamides J. Biol. Chem. 277 2002 20869 20876
184. G.G. Muccioli, and N. Stella Microglia produce and hydrolyze palmitoylethanolamide Neuropharmacology 54 2008 16 22
185. Y. Okamoto, J. Morishita, K. Tsuboi, T. Tonai, and N. Ueda Molecular characterization of a phospholipase D generating anandamide and its congeners J. Biol. Chem. 279 2004 5298 5305
186. B.F. Cravatt, D.K. Giang, S.P. Mayfield, D.L. Boger, R.A. Lerner, and N.B. Gilula Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides Nature 384 1996 83 87
187. N. Ueda, K. Yamanaka, and S. Yamamoto Purification and characterization of an acid amidase selective for N-palmitoylethanolamine, a putative endogenous anti-inflammatory substance J. Biol. Chem. 276 2001 35552 35557
188. D.K. Giang, and B.F. Cravatt Molecular characterization of human and mouse fatty acid amide hydrolases Proc. Natl. Acad. Sci. U. S. A. 94 1997 2238 2242
189. L.Y. Zhao, K. Tsuboi, Y. Okamoto, S. Nagahata, and N. Ueda Proteolytic activation and glycosylation of N-acylethanolamine-hydrolyzing acid amidase, a lysosomal enzyme involved in the endocannabinoid metabolism Biochim. Biophys. Acta 2007 1771 1397 1405
190. N. Ueda, K. Tsuboi, and T. Uyama Metabolism of endocannabinoids and related N-acylethanolamines: canonical and alternative pathways FEBS J. 280 2013 1874 1894
191. K. Tsuboi, Y.X. Sun, Y. Okamoto, N. Araki, T. Tonai, and N. Ueda Molecular characterization of N-acylethanolamine-hydrolyzing acid amidase, a novel member of the choloylglycine hydrolase family with structural and functional similarity to acid ceramidase J. Biol. Chem. 280 2005 11082 11092
192. K. Tsuboi, L.Y. Zhao, Y. Okamoto, N. Araki, M. Ueno, H. Sakamoto, and et al. Predominant expression of lysosomal N-acylethanolamine-hydrolyzing acid amidase in macrophages revealed by immunochemical studies Biochim. Biophys. Acta 2007 1771 623 632
193. S. Vandevoorde, K. Tsuboi, N. Ueda, K.O. Jonsson, C.J. Fowler, and D.M. Lambert Esters, retroesters, and a retroamide of palmitic acid: pool for the first selective inhibitors of N-palmitoylethanolamine-selective acid amidase J. Med. Chem. 46 2003 4373 4376
194. C. Saturnino, S. Petrosino, A. Ligresti, C. Palladino, G. De Martino, T. Bisogno, and et al. Synthesis and biological evaluation of new potential inhibitors of N-acylethanolamine hydrolyzing acid amidase Bioorg. Med. Chem. Lett. 20 2010 1210 1213
195. K. Tsuboi, C. Hilligsmann, S. Vandevoorde, D.M. Lambert, and N. Ueda N-cyclohexanecarbonylpentadecylamine: a selective inhibitor of the acid amidase hydrolysing N-acylethanolamines, as a tool to distinguish acid amidase from fatty acid amide hydrolase Biochem. J. 379 2004 99 106
196. Y. Li, L. Yang, L. Chen, C. Zhu, R. Huang, X. Zheng, and et al. Design and synthesis of potent N-acylethanolamine-hydrolyzing acid amidase (NAAA) inhibitor as anti-inflammatory compounds PLoS One 7 2012 e43023
197. C. Solorzano, C. Zhu, N. Battista, G. Astarita, A. Lodola, S. Rivara, and et al. Selective N-acylethanolamine-hydrolyzing acid amidase inhibition reveals a key role for endogenous palmitoylethanolamide in inflammation Proc. Natl. Acad. Sci. U. S. A. 106 2009 20966 20971
198. C. Solorzano, F. Antonietti, A. Duranti, A. Tontini, S. Rivara, A. Lodola, and et al. Synthesis and structure-activity relationships of N-(2-oxo-3-oxetanyl)amides as N-acylethanolamine-hydrolyzing acid amidase inhibitors J. Med. Chem. 53 2010 5770 5781
199. A. Duranti, A. Tontini, F. Antonietti, F. Vacondio, A. Fioni, C. Silva, and et al. N-(2-oxo-3-oxetanyl)carbamic acid esters as N-acylethanolamine acid amidase inhibitors: synthesis and structure-activity and structure-property relationships J. Med. Chem. 55 2012 4824 4836
200. S. Ponzano, F. Bertozzi, L. Mengatto, M. Dionisi, A. Armirotti, E. Romeo, and et al. Synthesis and structure-activity relationship (SAR) of 2-methyl-4-oxo-3-oxetanylcarbamic acid esters, a class of potent N-acylethanolamine acid amidase (NAAA) inhibitors J. Med. Chem. 56 2013 6917 6934
201. O. Sasso, G. Moreno-Sanz, C. Martucci, N. Realini, M. Dionisi, L. Mengatto, and et al. Antinociceptive effects of the N-acylethanolamine acid amidase inhibitor ARN077 in rodent pain models Pain 154 2013 350 360
202. A. Fiasella, A. Nuzzi, M. Summa, A. Armirotti, G. Tarozzo, G. Tarzia, and et al. 3-Aminoazetidin-2-one derivatives as N-acylethanolamine acid amidase (NAAA) inhibitors suitable for systemic administration ChemMedChem 9 2014 1602 1614
203. T. Tamura, T. Shirai, N. Kosaka, K. Ohmori, and N. Takafumi Pharmacological studies of diacerein in animal models of inflammation, arthritis and bone resorption Eur. J. Pharmacol. 448 2002 81 87
204. N.L. Quintão, R. Medeiros, A.R. Santos, M.M. Campos, and J.B. Calixto The effects of diacerein on mechanical allodynia in inflammatory and neuropathic models of nociception in mice Anesth. Analg. 101 2005 1763 1769
205. S. Petrosino, A. Ahmad, G. Marcolongo, E. Esposito, M. Allarà, R. Verde, and et al. Diacerein is a potent and selective inhibitor of palmitoylethanolamide inactivation with analgesic activity in a rat model of acute inflammatory pain Pharmacol. Res. 91 2015 9 14
206. L. Facci, R. Dal Toso, S. Romanello, A. Buriani, S.D. Skaper, and A. Leon Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide Proc. Natl. Acad. Sci. U. S. A. 92 1995 3376 3380
207. A. Calignano, G. La Rana, A. Giuffrida, and D. Piomelli Control of pain initiation by endogenous cannabinoids Nature 394 1998 277 281
208. B. Costa, S. Conti, G. Giagnoni, and M. Colleoni Therapeutic effect of the endogenous fatty acid amide, palmitoylethanolamide, in rat acute inflammation: inhibition of nitric oxide and cyclo-oxygenase systems Br. J. Pharmacol. 137 2002 413 420
209. J. Lo Verme, J. Fu, G. Astarita, G. La Rana, R. Russo, A. Calignano, and et al. The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide Mol. Pharmacol. 67 2005 15 19
210. V. Di Marzo, D. Melck, P. Orlando, T. Bisogno, O. Zagoory, M. Bifulco, and et al. Palmitoylethanolamide inhibits the expression of fatty acid amide hydrolase and enhances the anti-proliferative effect of anandamide in human breast cancer cells Biochem. J. 358 2001 249 255
211. W.S. Ho, D.A. Barrett, and M.D. Randall 'Entourage effects of N-palmitoylethanolamide and N-oleoylethanolamide on vasorelaxation to anandamide occur through TRPV1 receptors Br. J. Pharmacol. 155 2008 837 846
212. B. Costa, F. Comelli, I. Bettoni, M. Colleoni, and G. Giagnoni The endogenous fatty acid amide, palmitoylethanolamide, has anti-allodynic and anti-hyperalgesic effects in a murine model of neuropathic pain: involvement of CB(1), TRPV1 and PPARgamma receptors and neurotrophic factors Pain 139 2008 541 550
213. V. de Novellis, L. Luongo, F. Guida, L. Cristino, E. Palazzo, R. Russo, and et al. Effects of intra-ventrolateral periaqueductal grey palmitoylethanolamide on thermoceptive threshold and rostral ventromedial medulla cell activity Eur. J. Pharmacol. 676 2012 41 50
214. C. García Mdel, E. Adler-Graschinsky, and S.M. Celuch Enhancement of the hypotensive effects of intrathecally injected endocannabinoids by the entourage compound palmitoylethanolamide Eur. J. Pharmacol. 610 2009 75 80
215. 1 receptors and TRPV1 channels Br. J. Pharmacol. 171 2014 4026 4037
216. M. Karsak, E. Gaffal, R. Date, L. Wang-Eckhardt, J. Rehnelt, S. Petrosino, and et al. Attenuation of allergic contact dermatitis through the endocannabinoid system Science 316 2007 1494 1497
217. P.M. Zygmunt, A. Ermund, P. Movahed, D.A. Andersson, C. Simonsen, B.A. Jönsson, and et al. Monoacylglycerols activate TRPV1 - a link between phospholipase C and TRPV1 PLoS One 8 2013 e81618
218. S. Petrosino, A. Schiano Moriello, S. Cerrato, M. Fusco, A. Puigdemont, L. De Petrocellis, and V. Di Marzo The anti-inflammatory mediator palmitoylethanolamide enhances the levels of 2-arachidonoyl-glycerol and potentiates its actions at TRPV1 cation channels Br. J. Pharmacol. 2015
219. Y. Marchalant, K. Baranger, G.L. Wenk, M. Khrestchatisky, and S. Rivera Can the benefits of cannabinoid receptor stimulation on neuroinflammation, neurogenesis and memory during normal aging be useful in AD prevention? J. Neuroinflammation 9 2012 10
220. V. Micale, C. Mazzola, and F. Drago Endocannabinoids and neurodegenerative diseases Pharmacol. Res. 56 2007 382 392
221. T. Bisogno, and V. Di Marzo Cannabinoid receptors and endocannabinoids: role in neuroinflammatory and neurodegenerative disorders CNS Neurol. Disord. Drug Targets 9 2010 564 573
222. A. Serrano-Pozo, M.P. Frosch, E. Masliah, and B.T. Hyman Neuropathological alterations in Alzheimer disease Cold Spring Harb. Perspect. Med. 1 2011 a006189
223. C. Benito, E. Núñez, R.M. Tolón, E.J. Carrier, A. Rábano, C.J. Hillard, and et al. Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimers disease brains J. Neurosci. 23 2003 11136 11141
224. B.G. Ramïrez, C. Blázquez, T. Gómez del Pulgar, M. Guzmán, and M.L. de Ceballos Prevention of Alzheimers disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation J. Neurosci. 25 2005 1904 1910
225. E. Aso, S. Juvés, R. Maldonado, and I. Ferrer CB2 cannabinoid receptor agonist ameliorates Alzheimer-like phenotype in AβPP/PS1 mice J Alzheimers Dis 35 4 2013 847 858
226. N.G. Milton Anandamide and noladin ether prevent neurotoxicity of the human amyloid-beta peptide Neurosci. Lett. 332 2002 127 130
227. M. van der Stelt, C. Mazzola, G. Esposito, I. Matias, S. Petrosino, D. De Filippis, and et al. Endocannabinoids and beta-amyloid-induced neurotoxicity in vivo: effect of pharmacological elevation of endocannabinoid levels Cell. Mol. Life Sci. 63 2006 1410 1424
228. E. Aso, E. Palomer, S. Juvés, R. Maldonado, F.J. Muñoz, and I. Ferrer CB1 agonist ACEA protects neurons and reduces the cognitive impairment of AβPP/PS1 mice J. Alzheimers Dis. 30 2012 439 459
229. M. Haghani, M. Shabani, M. Javan, F. Motamedi, and M. Janahmadi CB1 cannabinoid receptor activation rescues amyloid β-induced alterations in behaviour and intrinsic electrophysiological properties of rat hippocampal CA1 pyramidal neurones Cell. Physiol. Biochem. 29 2012 391 406
230. M. Haghani, M. Janahmadi, and M. Shabani Protective effect of cannabinoid CB1 receptor activation against altered intrinsic repetitive firing properties induced by Aβ neurotoxicity Neurosci. Lett. 507 2012 33 37
231. A.M. Martín-Moreno, D. Reigada, B.G. Ramírez, R. Mechoulam, N. Innamorato, A. Cuadrado, and et al. Cannabidiol and other cannabinoids reduce microglial activation in vitro and in vivo: relevance to Alzheimers disease Mol. Pharmacol. 79 2011 964 973
232. G. Esposito, D. De Filippis, R. Carnuccio, A.A. Izzo, and T. Iuvone The marijuana component cannabidiol inhibits beta-amyloid-induced tau protein hyperphosphorylation through Wnt/beta-catenin pathway rescue in PC12 cells J. Mol. Med. 84 2006 253 258
233. C. Mazzola, V. Micale, and F. Drago Amnesia induced by beta-amyloid fragments is counteracted by cannabinoid CB1 receptor blockade Eur. J. Pharmacol. 477 2003 219 225
234. J. Mulder, M. Zilberter, S.J. Pasquaré, A. Alpár, G. Schulte, S.G. Ferreira, and et al. Molecular reorganization of endocannabinoid signalling in Alzheimers disease Brain 134 2011 1041 1060
235. K.M. Jung, G. Astarita, S. Yasar, V. Vasilevko, D.H. Cribbs, E. Head, and et al. An amyloid β42-dependent deficit in anandamide mobilization is associated with cognitive dysfunction in Alzheimers disease Neurobiol. Aging 33 2012 1522 1532
236. C. Altamura, M. Ventriglia, M.G. Martini, D. Montesano, Y. Errante, F. Piscitelli, and et al. Elevation of plasma 2-arachidonoylglycerol levels in Alzheimers disease patients as a potential protective mechanism against neurodegenerative decline J. Alzheimers Dis. 2015 (Epub ahead of print)
237. G. Di Iorio, M. Lupi, F. Sarchione, I. Matarazzo, R. Santacroce, F. Petruccelli, and et al. The endocannabinoid system: a putative role in neurodegenerative diseases Int. J. High Risk Behav. Addict. 2 2013 100 106
238. J.P. Steiner, G.S. Hamilton, D.T. Ross, H.L. Valentine, H. Guo, M.A. Connolly, and et al. Neurotrophic immunophilin ligands stimulate structural and functional recovery in neurodegenerative animal models Proc. Natl. Acad. Sci. U. S. A. 94 1997 2019 2024
239. M. Melis, and M. Pistis Endocannabinoid signaling in midbrain dopamine neurons: more than physiology? Curr. Neuropharmacol. 5 2007 268 277
240. V. Pisani, V. Moschella, M. Bari, F. Fezza, S. Galati, G. Bernardi, and et al. Dynamic changes of anandamide in the cerebrospinal fluid of Parkinsons disease patients Mov. Disord. 25 2010 920 924
241. M. Maccarrone, P. Gubellini, M. Bari, B. Picconi, N. Battista, D. Centonze, and et al. Levodopa treatment reverses endocannabinoid system abnormalities in experimental parkinsonism J. Neurochem. 85 2003 1018 1025
242. M. van der Stelt, S.H. Fox, M. Hill, A.R. Crossman, S. Petrosino, V. Di Marzo, and et al. A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinsons disease FASEB J. 19 2005 1140 1142
243. V. Di Marzo, M.P. Hill, T. Bisogno, A.R. Crossman, and J.M. Brotchie Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinsons disease FASEB J. 14 2000 1432 1438
244. P. Mailleux, and J.J. Vanderhaeghen Dopaminergic regulation of cannabinoid receptor mRNA levels in the rat caudate-putamen: an in situ hybridization study J. Neurochem. 61 1993 1705 1712
245. J. Romero, F. Berrendero, A. Pérez-Rosado, J. Manzanares, A. Rojo, J.J. Fernández-Ruiz, and et al. Unilateral 6-hydroxydopamine lesions of nigrostriatal dopaminergic neurons increased CB1 receptor mRNA levels in the caudate-putamen Life Sci. 66 2000 485 494
246. P. Gubellini, B. Picconi, M. Bari, N. Battista, P. Calabresi, D. Centonze, and et al. Experimental parkinsonism alters endocannabinoid degradation: implications for striatal glutamatergic transmission J. Neurosci. 22 2002 6900 6907
247. I. Lastres-Becker, M. Cebeira, M.L. de Ceballos, B.Y. Zeng, P. Jenner, J.A. Ramos, and et al. Increased cannabinoid CB1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinsons syndrome and of MPTP-treated marmosets Eur. J. Neurosci. 14 2001 1827 1832
248. M.J. Hurley, D.C. Mash, and P. Jenner Expression of cannabinoid CB1 receptor mRNA in basal ganglia of normal and parkinsonian human brain J. Neural Transm. 110 2003 1279 1288
249. J.P. Meschler, A.C. Howlett, and B.K. Madras Cannabinoid receptor agonist and antagonist effects on motor function in normal and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP)-treated non-human primates Psychopharmacology 156 2001 79 85
250. F. El-Banoua, I. Caraballo, J.A. Flores, B. Galan-Rodriguez, and E. Fernandez-Espejo Effects on turning of microinjections into basal ganglia of D(1) and D(2) dopamine receptors agonists and the cannabinoid CB(1) antagonist SR141716A in a rat Parkinsons model Neurobiol. Dis. 16 2004 377 385
251. V. Mesnage, J.L. Houeto, A.M. Bonnet, I. Clavier, I. Arnulf, F. Cattelin, and et al. Neurokinin B, neurotensin, and cannabinoid receptor antagonists and Parkinson disease Clin. Neuropharmacol. 27 2004 108 110
252. S. González, C. Scorticati, M. García-Arencibia, R. de Miguel, J.A. Ramos, and J. Fernández-Ruiz Effects of rimonabant, a selective cannabinoid CB1 receptor antagonist, in a rat model of Parkinsons disease Brain Res. 1073-1074 2006 209 219
253. A. Pisani, P. Bonsi, B. Picconi, M. Tolu, P. Giacomini, and E. Scarnati Role of tonically-active neurons in the control of striatal function: cellular mechanisms and behavioral correlates Prog. Neuro-Psychopharmacol. Biol. Psychiatry 25 2001 211 230
254. D.A. Price, A.A. Martinez, A. Seillier, W. Koek, Y. Acosta, E. Fernandez, R. Strong, B. Lutz, G. Marsicano, J.L. Roberts, and A. Giuffrida WIN55,212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinsons disease Eur. J. Neurosci. 29 11 Jun 2009 2177 2186
255. 9-THCV in animal models of Parkinsons disease Br. J. Pharmacol. 163 7 Aug 2011 1495 1506
256. D. Fernández-Suárez, M. Celorrio, J.I. Riezu-Boj, A. Ugarte, R. Pacheco, H. González, J. Oyarzabal, C.J. Hillard, R. Franco, and M.S. Aymerich Monoacylglycerol lipase inhibitor JZL184 is neuroprotective and alters glial cell phenotype in the chronic MPTP mouse model Neurobiol. Aging 35 11 Nov 2014 2603 2616
257. M.S. Aymerich, E. Rojo-Bustamante, C. Molina, M. Celorrio, J.A. Sánchez-Arias, and R. Franco Neuroprotective effect of JZL184 in MPP +-treated SH-SY5Y cells through CB2 receptors Mol. Neurobiol. 2015 (Epub ahead of print)
258. A. Ternianov, J.M. Pérez-Ortiz, M.E. Solesio, M.S. García-Gutiérrez, A. Ortega-Álvaro, F. Navarrete, C. Leiva, M.F. Galindo, and J. Manzanares Overexpression of CB2 cannabinoid receptors results in neuroprotection against behavioral and neurochemical alterations induced by intracaudate administration of 6-hydroxydopamine Neurobiol. Aging 33 2 Feb 2012 421.e1 421.e16
259. M. Glass, M. Dragunow, and R.L. Faull The pattern of neurodegeneration in Huntingtons disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntingtons disease Neuroscience 97 2000 505 519
260. K.L. Allen, H.J. Waldvogel, M. Glass, and R.L. Faull Cannabinoid (CB(1)), GABA(A) and GABA(B) receptor subunit changes in the globus pallidus in Huntingtons disease J. Chem. Neuroanat. 37 2009 266 281
261. J. Palazuelos, T. Aguado, M.R. Pazos, B. Julien, C. Carrasco, E. Resel, and et al. Microglial CB2 cannabinoid receptors are neuroprotective in Huntingtons disease excitotoxicity Brain 132 2009 3152 3164
262. N. Battista, M. Bari, A. Tarditi, C. Mariotti, A.C. Bachoud-Lévi, C. Zuccato, and et al. Severe deficiency of the fatty acid amide hydrolase (FAAH) activity segregates with the Huntingtons disease mutation in peripheral lymphocytes Neurobiol. Dis. 27 2007 108 116
263. M.J. Dowie, H.B. Bradshaw, M.L. Howard, L.F. Nicholson, R.L. Faull, A.J. Hannan, and et al. Altered CB1 receptor and endocannabinoid levels precede motor symptom onset in a transgenic mouse model of Huntingtons disease Neuroscience 163 2009 456 465
264. T. Bisogno, A. Martire, S. Petrosino, P. Popoli, and V. Di Marzo Symptom-related changes of endocannabinoid and palmitoylethanolamide levels in brain areas of R6/2 mice, a transgenic model of Huntingtons disease Neurochem. Int. 52 2008 307 313
265. C. Blázquez, A. Chiarlone, L. Bellocchio, E. Resel, P. Pruunsild, D. García-Rincón, and et al. The CB1 cannabinoid receptor signals striatal neuroprotection via a PI3K/Akt/mTORC1/BDNF pathway Cell Death Differ. 2015 (Epub ahead of print)
266. I. Lastres-Becker, N. Bizat, F. Boyer, P. Hantraye, E. Brouillet, and J. Fernández-Ruiz Effects of cannabinoids in the rat model of Huntingtons disease generated by an intrastriatal injection of malonate Neuroreport 14 2003 813 816
267. O. Sagredo, S. González, I. Aroyo, M.R. Pazos, C. Benito, I. Lastres-Becker, and et al. Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: relevance for Huntingtons disease Glia 57 2009 1154 1167
268. S. Valdeolivas, M.R. Pazos, T. Bisogno, F. Piscitelli, F.A. Iannotti, M. Allarà, and et al. The inhibition of 2-arachidonoyl-glycerol (2-AG) biosynthesis, rather than enhancing striatal damage, protects striatal neurons from malonate-induced death: a potential role of cyclooxygenase-2-dependent metabolism of 2-AG Cell Death Dis. 4 2013 e862
269. S. Frank Treatment of Huntingtons disease Neurotherapeutics 11 1 2014 153 160
270. B. Kluger, P. Triolo, W. Jones, and J. Jankovic The therapeutic potential of cannabinoids for movement disorders Mov. Disord. 30 2015 313 327
271. J. Fernández-Ruiz, O. Sagredo, M.R. Pazos, C. García, R. Pertwee, R. Mechoulam, and et al. Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid? Br. J. Clin. Pharmacol. 75 2013 323 333
272. M.R. Pazos, O. Sagredo, and J. Fernández-Ruiz The endocannabinoid system in Huntingtons disease Curr. Pharm. Des. 14 2008 2317 2325
273. J. Fernández-Ruiz, C. García, O. Sagredo, M. Gómez-Ruiz, and E. de Lago The endocannabinoid system as a target for the treatment of neuronal damage Expert Opin. Ther. Targets 14 2010 387 404
274. 1 cannabinoid receptor signals striatal neuroprotection via a PI3K/Akt/mTORC1/BDNF pathway Cell Death Differ 22 10 2015 1618 1629
275. S. Valdeolivas, V. Satta, R.G. Pertwee, J. Fernández-Ruiz, and O. Sagredo Sativex-like combination of phytocannabinoids is neuroprotective in malonate-lesioned rats, an inflammatory model of Huntingtons disease: role of CB1 and CB2 receptors ACS Chem. Neurosci. 3 2012 400 406
276. A. Curtis, and H. Rickards Nabilone could treat chorea and irritability in Huntingtons disease J. Neuropsychiatr. Clin. Neurosci. 18 2006 553 554
277. A. Curtis, I. Mitchell, S. Patel, N. Ives, and H. Rickards A pilot study using nabilone for symptomatic treatment in Huntingtons disease Mov. Disord. 24 2009 2254 2259
278. K.R. Müller-Vahl, U. Schneider, and H.M. Emrich Nabilone increases choreatic movements in Huntingtons disease Mov. Disord. 14 1999 1038 1040
279. W.G. Notcutt Clinical use of cannabinoids for symptom control in multiple sclerosis Neurotherapeutics 2015 (Epub ahead of print)
280. A. Feinstein, J. Freeman, and A.C. Lo Treatment of progressive multiple sclerosis: what works, what does not, and what is needed Lancet Neurol. 14 2015 194 207
281. L. Belbasis, V. Bellou, E. Evangelou, J.P. Ioannidis, and I. Tzoulaki Environmental risk factors and multiple sclerosis: an umbrella review of systematic reviews and meta-analyses Lancet Neurol. 14 2015 263 273
282. A. Compston, and A. Coles Multiple sclerosis Lancet 372 2008 1502 1517
283. G. Pryce, A. Cabranes, J. Fernández-Ruiz, T. Bisogno, V. Di Marzo, J.Z. Long, B.F. Cravatt, G. Giovannoni, and D. Baker Control of experimental spasticity by targeting the degradation of endocannabinoids using selective fatty acid amide hydrolase inhibitors Mult. Scler. 19 2013 1896 1904
284. A. Witting, L. Chen, E. Cudaback, A. Straiker, L. Walter, B. Rickman, and et al. Experimental autoimmune encephalomyelitis disrupts endocannabinoid-mediated neuroprotection Proc. Natl. Acad. Sci. U. S. A. 103 2006 6362 6367
285. J. Wen, R. Ribeiro, M. Tanaka, and Y. Zhang Activation of CB2 receptor is required for the therapeutic effect of ABHD6 inhibition in experimental autoimmune encephalomyelitis Neuropharmacology 99 2015 196 209
286. K. Maresz, G. Pryce, E.D. Ponomarev, G. Marsicano, J.L. Croxford, L.P. Shriver, and et al. Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells Nat. Med. 13 2007 492 497
287. C. Ni, C. Wang, J. Zhang, L. Qu, X. Liu, Y. Lu, and et al. Interferon-γ safeguards blood-brain barrier during experimental autoimmune encephalomyelitis Am. J. Pathol. 184 2014 3308 3320
288. W. Kong, H. Li, R.F. Tuma, and D. Ganea Selective CB2 receptor activation ameliorates EAE by reducing Th17 differentiation and immune cell accumulation in the CNS Cell. Immunol. 287 2014 1 17
289. 2 receptor agonist, WIN 55,212-2, exerts its therapeutic effect in a viral autoimmune model of multiple sclerosis by restoring self-tolerance to myelin Neuropharmacology 63 2012 385 393
290. R. Ribeiro, F. Yu, J. Wen, A. Vana, and Y. Zhang Therapeutic potential of a novel cannabinoid agent CB52 in the mouse model of experimental autoimmune encephalomyelitis Neuroscience 254 2013 427 442
291. D. Baker, and G. Pryce The endocannabinoid system and multiple sclerosis Curr. Pharm. Des. 14 2008 2326 2336
292. A. Feliú, M. Moreno-Martet, M. Mecha, F.J. Carrillo-Salinas, E. de Lago, J. Fernández-Ruiz, and C. Guaza A Sativex(®)-like combination of phytocannabinoids as a disease-modifying therapy in a viral model of multiple sclerosis Br. J. Pharmacol. 172 14 Jul 2015 3579 3595
293. E. de Lago, M. Gómez-Ruiz, M. Moreno-Martet, and J. Fernández-Ruiz Cannabinoids, multiple sclerosis and neuroprotection Expert. Rev. Clin. Pharmacol. 2 6 Nov 2009 645 660
294. W.D. Lyman, G.A. Abrams, and C.S. Raine Experimental autoimmune encephalomyelitis: isolation and characterization of inflammatory cells from the central nervous system J. Neuroimmunol. 25 2-3 Dec 1989 195 201
295. A.L. Arévalo-Martín, J.M. Vela, E. Molina-Holgado, J. Borrell, and C. Guaza Therapeutic action of cannabinoids in a murine model of multiple sclerosis J. Neurosci. 23 7 Apr 1 2003 2511 2516
296. G. Pryce, Z. Ahmed, D.J. Hankey, S.J. Jackson, J.L. Croxford, J.M. Pocock, C. Ledent, A. Petzold, A.J. Thompson, G. Giovannoni, M.L. Cuzner, and D. Baker Cannabinoids inhibit neurodegeneration in models of multiple sclerosis. Cannabinoids inhibit neurodegeneration in models of multiple sclerosis Brain 126 Pt 10 2003 2191 2202
297. A.J. Sánchez, P. González-Pérez, I. Galve-Roperh, and A. García-Merino R-(+)-[2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)-pyrrolo-[1,2,3-de]-1,4-benzoxazin-6-yl]-1-naphtalenylmethanone (WIN-2) ameliorates experimental autoimmune encephalomyelitis and induces encephalitogenic T cell apoptosis: partial involvement of the CB(2) receptor Biochem Pharmacol 72 12 2006 1697 1706
298. E. Kozela, N. Lev, N. Kaushansky, R. Eilam, N. Rimmerman, R. Levy, A. Ben-Nun, A. Juknat, and Z. Vogel Cannabidiol inhibits pathogenic T cells, decreases spinal microglial activation and ameliorates multiple sclerosis-like disease in C57BL/6 mice Br. J. Pharmacol. 163 7 2011 1507 1519
299. M. Mecha, A. Feliú, P.M. Iñigo, L. Mestre, F.J. Carrillo-Salinas, and C. Guaza Cannabidiol provides long-lasting protection against the deleterious effects of inflammation in a viral model of multiple sclerosis: a role for A2A receptors Neurobiol. Dis. 59 2013 141 150
300. R.E. Blair, L.S. Deshpande, S. Sombati, K.W. Falenski, B.R. Martin, and R.J. DeLorenzo Activation of the cannabinoid type-1 receptor mediates the anticonvulsant properties of cannabinoids in the hippocampal neuronal culture models of acquired epilepsy and status epilepticus J. Pharmacol. Exp. Ther. 317 2006 1072 1078
301. L.S. Deshpande, S. Sombati, R.E. Blair, D.S. Carter, B.R. Martin, and R.J. DeLorenzo Cannabinoid CB1 receptor antagonists cause status epilepticus-like activity in the hippocampal neuronal culture model of acquired epilepsy Neurosci. Lett. 411 2007 11 16
302. S. Guggenhuber, K. Monory, B. Lutz, and M. Klugmann AAV vector-mediated overexpression of CB1 cannabinoid receptor in pyramidal neurons of the hippocampus protects against seizure-induced excitoxicity PLoS One 5 2010 e15707
303. K. Monory, F. Massa, M. Egertová, M. Eder, H. Blaudzun, R. Westenbroek, and et al. The endocannabinoid system controls key epileptogenic circuits in the hippocampus Neuron 51 2006 455 466
304. M.J. Wallace, R.E. Blair, K.W. Falenski, B.R. Martin, and R.J. DeLorenzo The endogenous cannabinoid system regulates seizure frequency and duration in a model of temporal lobe epilepsy J. Pharmacol. Exp. Ther. 307 2003 129 137
305. P. Zogopoulos, I. Vasileiou, E. Patsouris, and S. Theocharis The neuroprotective role of endocannabinoids against chemical-induced injury and other adverse effects J. Appl. Toxicol. 33 2013 246 264
306. G. Marsicano, S. Goodenough, K. Monory, H. Hermann, M. Eder, A. Cannich, and et al. CB1 cannabinoid receptors and on-demand defense against excitotoxicity Science 302 2003 84 88
307. V. Naidoo, S.P. Nikas, D.A. Karanian, J. Hwang, J. Zhao, J.T. Wood, and et al. A new generation fatty acid amide hydrolase inhibitor protects against kainate-induced excitotoxicity J. Mol. Neurosci. 43 2011 493 502
308. D.A. Karanian, S.L. Karim, J.T. Wood, J.S. Williams, S. Lin, A. Makriyannis, and B.A. Bahr Endocannabinoid enhancement protects against kainic acid-induced seizures and associated brain damage J. Pharmacol. Exp. Ther. 322 2007 1059 1066
309. R.L. Kow, K. Jiang, A.V. Naydenov, J.H. Le, N. Stella, and N.M. Nathanson Modulation of pilocarpine-induced seizures by cannabinoid receptor 1 PLoS One 9 2014 e95922
310. B. Lutz On-demand activation of the endocannabinoid system in the control of neuronal excitability and epileptiform seizures Biochem. Pharmacol. 68 2004 1691 1698
311. A. Ludányi, L. Eross, S. Czirják, J. Vajda, P. Halász, M. Watanabe, and et al. Downregulation of the CB1 cannabinoid receptor and related molecular elements of the endocannabinoid system in epileptic human hippocampus J. Neurosci. 28 2008 2976 2990
312. F.J. Sun, W. Guo, D.H. Zheng, C.Q. Zhang, S. Li, S.Y. Liu, and et al. Increased expression of TRPV1 in the cortex and hippocampus from patients with mesial temporal lobe epilepsy J. Mol. Neurosci. 49 2013 182 193
313. M.D. Bhaskaran, and B.N. Smith Effects of TRPV1 activation on synaptic excitation in the dentate gyrus of a mouse model of temporal lobeepilepsy Exp. Neurol. 223 2010 529 536
314. M. Shirazi, M. Izadi, M. Amin, M.E. Rezvani, A. Roohbakhsh, and A. Shamsizadeh Involvement of central TRPV1 receptors in pentylenetetrazole and amygdala-induced kindling in male rats Neurol. Sci. 35 2014 1235 1241
315. V. Micale, L. Cristino, A. Tamburella, S. Petrosino, G.M. Leggio, F. Drago, and V. Di Marzo Altered responses of dopamine D3 receptor null mice to excitotoxic or anxiogenic stimuli: possible involvement of the endocannabinoid and endovanilloid systems Neurobiol. Dis. 36 1 2009 70 80
316. M. Fidaleo, F. Fanelli, M.P. Ceru, and S. Moreno Neuroprotective properties of peroxisome proliferator-activated receptor alpha (PPARα) and its lipid ligands Curr Med Chem 21 24 2014 2803 2821
317. S.D. Skaper, A. Buriani, R. Dal Toso, L. Petrelli, S. Romanello, L. Facci, and et al. The ALIAmide palmitoylethanolamide and cannabinoids, but not anandamide, are protective in a delayed postglutamate paradigm of excitotoxic death in cerebellar granule neurons Proc. Natl. Acad. Sci. U. S. A. 93 1996 3984 3989
318. F. Loría, S. Petrosino, L. Mestre, A. Spagnolo, F. Correa, M. Hernangómez, and et al. Study of the regulation of the endocannabinoid system in a virus model of multiple sclerosis reveals a therapeutic effect of palmitoylethanolamide Eur. J. Neurosci. 28 2008 633 641
319. A. Rahimi, M. Faizi, F. Talebi, F. Noorbakhsh, F. Kahrizi, and N. Naderi Interaction between the protective effects of cannabidiol and palmitoylethanolamide in experimental model of multiple sclerosis in C57BL/6 mice Neuroscience 290 2015 279 287
320. W.R. Schäbitz, A. Giuffrida, C. Berger, A. Aschoff, M. Schwaninger, S. Schwab, and et al. Release of fatty acid amides in a patient with hemispheric stroke: a microdialysis study Stroke 33 2002 2112 2114
321. A. Franklin, S. Parmentier-Batteur, L. Walter, D.A. Greenberg, and N. Stella Palmitoylethanolamide increases after focal cerebral ischemia and potentiates microglial cell motility J. Neurosci. 23 2003 7767 7775
322. M. Naccarato, D. Pizzuti, S. Petrosino, M. Simonetto, L. Ferigo, F.C. Grandi, and et al. Possible anandamide and palmitoylethanolamide involvement in human stroke Lipids Health Dis. 9 2010 47
323. A. Ahmad, T. Genovese, D. Impellizzeri, R. Crupi, E. Velardi, A. Marino, E. Esposito, and S. Cuzzocrea Reduction of ischemic brain injury by administration of palmitoylethanolamide after transient middle cerebral artery occlusion in rats Brain Res. 1477 Oct 5 2012 45 58
324. W.H. Hind, C. Tufarelli, M. Neophytou, S.I. Anderson, T.J. England, and S.E. OSullivan Endocannabinoids modulate human blood-brain barrier permeability in vitro Br. J. Pharmacol. 172 12 Jun 2015 3015 3027
325. S.D. Skaper, L. Facci, M. Barbierato, M. Zusso, G. Bruschetta, D. Impellizzeri, S. Cuzzocrea, and P. Giusti N-palmitoylethanolamine and neuroinflammation: a novel therapeutic strategy of resolution Mol. Neurobiol. 52 2 Oct 2015 1034 1042
326. F. Guida, L. Luongo, F. Marmo, R. Romano, M. Iannotta, F. Napolitano, C. Belardo, I. Marabese, A. DAniello, D. De Gregorio, F. Rossi, F. Piscitelli, R. Lattanzi, A. de Bartolomeis, A. Usiello, V. Di Marzo, V. de Novellis, and S. Maione Palmitoylethanolamide reduces pain-related behaviors and restores glutamatergic synapses homeostasis in the medial prefrontal cortex of neuropathic mice Mol. Brain 8 Aug 12 2015 47
327. S.D. Skaper, L. Facci, and P. Giusti Neuroinflammation, microglia and mast cells in the pathophysiology of neurocognitive disorders: a review CNS Neurol. Disord. Drug Targets 13 2014 1654 1666
328. C. Scuderi, M. Valenza, C. Stecca, G. Esposito, M.R. Carratù, and L. Steardo Palmitoylethanolamide exerts neuroprotective effects in mixed neuroglial cultures and organotypic hippocampal slices via peroxisome proliferator-activated receptor-α J. Neuroinflammation 9 2012 49
329. G. DAgostino, R. Russo, C. Avagliano, C. Cristiano, R. Meli, and A. Calignano Palmitoylethanolamide protects against the amyloid-β25-35-induced learning and memory impairment in mice, an experimental model of Alzheimer disease Neuropsychopharmacology 37 2012 1784 1792
330. C. Scuderi, C. Stecca, M. Valenza, P. Ratano, M.R. Bronzuoli, S. Bartoli, and et al. Palmitoylethanolamide controls reactive gliosis and exerts neuroprotective functions in a rat model of Alzheimers disease Cell Death Dis. 5 2014 e1419
331. I. Paterniti, M. Cordaro, M. Campolo, R. Siracusa, C. Cornelius, M. Navarra, and et al. Neuroprotection by association of palmitoylethanolamide with luteolin in experimental Alzheimers disease models: the control of neuroinflammation CNS Neurol. Disord. Drug Targets 13 2014 1530 1541
332. M. Cordaro, D. Impellizzeri, G. Bruschetta, R. Siracusa, R. Crupi, R. Di Paola, E. Esposito, and S. Cuzzocrea A novel protective formulation of palmitoylethanolamide in experimental model of contrast agent induced nephropathy Toxicol. Lett. 240 1 Jan 5 2016 10 21
333. E. Esposito, D. Impellizzeri, E. Mazzon, I. Paterniti, and S. Cuzzocrea Neuroprotective activities of palmitoylethanolamide in an animal model of Parkinsons disease PLoS One 7 2012 e41880
334. D.M. Lambert, S. Vandevoorde, G. Diependaele, S.J. Govaerts, and A.R. Robert Anticonvulsant activity of N-palmitoylethanolamide, a putative endocannabinoid, in mice Epilepsia 42 2001 321 327
335. A.H. Sheerin, X. Zhang, D.M. Saucier, and M.E. Corcoran Selective antiepileptic effects of N-palmitoylethanolamide, a putative endocannabinoid Epilepsia 45 2004 1184 1188
336. R. Citraro, E. Russo, F. Scicchitano, C.M. van Rijn, D. Cosco, C. Avagliano, and et al. Antiepileptic action of N-palmitoylethanolamine through CB1 and PPAR-α receptor activation in a genetic model of absence epilepsy Neuropharmacology 69 2013 115 126
337. I. Aghaei, M. Rostampour, M. Shabani, N. Naderi, F. Motamedi, P. Babaei, and et al. Palmitoylethanolamide attenuates PTZ-induced seizures through CB1 and CB2 receptors Epilepsy Res. 117 2015 23 28
338. H.S. Hansen Palmitoylethanolamide and other anandamide congeners. Proposed role in the diseased brain Exp. Neurol. 224 2010 48 55
339. H.S. Hansen, B. Moesgaard, H.H. Hansen, and G. Petersen N-acylethanolamines and precursor phospholipids - relation to cell injury Chem. Phys. Lipids 108 2000 135 150
340. T.A. Diep, A.N. Madsen, B. Holst, M.M. Kristiansen, N. Wellner, S.H. Hansen, and et al. Dietary fat decreases intestinal levels of the anorectic lipids through a fat sensor FASEB J. 25 2011 765 774
341. J. Fu, S. Gaetani, F. Oveisi, J. LoVerme, A. Serrano, F. Rodríguez de Fonseca, and et al. Oleoylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPARa Nature 425 2003 90 93
342. H.A. Overton, A.J. Babbs, S.M. Doel, M.C. Fyfe, L.S. Gardner, G. Griffin, and et al. Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small molecule hypophagic agents Cell Metab. 3 2006 167 175
343. K.B. Hansen, M.M. Rosenkilde, F.K. Knop, N. Wellner, T.A. Diep, J.F. Rehfeld, and et al. 2-Oleoyl glycerol is a GPR119 agonist and signals GLP-1 release in humans J. Clin. Endocrinol. Metab. 96 2011 E1409 E1417
344. P. Movahed, B.A.G. Jönsson, B. Birnir, J.A. Wingstrand, T.D. Jorgensen, A. Ermund, and et al. Endogenous unsaturated C18 N-acylethanolamines are vanilloid receptor (TRPV1) agonists J. Biol. Chem. 280 2005 38496 38504
345. F. Rodríguez de Fonseca, M. Navarro, R. Gómez, L. Escuredo, F. Nava, J. Fu, and et al. An anorexic lipid mediator regulated by feeding Nature 414 2001 209 212
346. M. Suardiaz, G. Estivill-Torrus, C. Goicoechea, A. Bilbao, and F. Rodríguez de Fonseca Analgesic properties of oleoylethanolamide (OEA) in visceral and inflammatory pain Pain 33 2007 99 110
347. A. Fan, X. Wu, H. Wu, L. Li, R. Huang, Y. Zhu, and et al. Atheroprotective effect of oleoylethanolamide (OEA) targeting oxidized LDL PLoS One 9 2014 e85337
348. B. Galan-Rodriguez, J. Suarez, R. Gonzalez-Aparicio, F.J. Bermudez-Silva, R. Maldonado, P. Robledo, and et al. Oleoylethanolamide exerts partial and dose-dependent neuroprotection of substantia nigra dopamine neurons Neuropharmacology 56 2009 653 664
349. P. Garg, R.S. Duncan, S. Kaja, A. Zabaneh, K.D. Chapman, and P. Koulen Lauroyl-ethanolamide and linoleoylethanolamide improve functional outcome in a rodent model for stroke Neurosci. Lett. 492 2011 134 138
350. Y. Zhou, L. Yang, A. Ma, X. Zhang, W. Li, W. Yang, and et al. Orally administered oleoylethanolamide protects mice from focal cerebral ischemic injury by activating peroxisome proliferator-activated receptor alpha Neuropharmacology 63 2012 242 249
351. C.J. Chu, S.M. Huang, L. De Petrocellis, T. Bisogno, S.A. Ewing, J.D. Miller, and et al. N-oleoyldopamine, a novel endogenous capsaicin-like lipid that produces hyperalgesia J. Biol. Chem. 278 2003 13633 13639
352. S. Raboune, J.M. Stuart, E. Leishman, S.M. Takacs, B. Rhodes, A. Basnet, and et al. Novel endogenous N-acyl amides activate TRPV1-4 receptors, BV-2 microglia, and are regulated in brain in an acute model of inflammation Front. Cell. Neurosci. 8 2014 195
353. D. Hauer, G. Schelling, H. Gola, P. Campolongo, J. Morath, B. Roozendaal, and et al. Plasma concentrations of endocannabinoids and related primary fatty acid amides in patients with post-traumatic stress disorder PLoS One 8 2013 e62741
354. C. Kulisch, and D. Albrecht Effects of single swim stress on changes in TRPV1-mediated plasticity in the amygdala Behav. Brain Res. 236 2013 344 349
355. T. Bisogno, D. Melck, L. De Petrocellis, MYu Bobrov, N.M. Gretskaya, V.V. Bezuglov, and et al. Arachidonoylserotonin and other novel inhibitors of fatty acid amide hydrolase Biochem. Biophys. Res. Commun. 248 1998 515 522
356. E. de Lago, S. Petrosino, M. Valenti, E. Morera, S. Ortega-Gutierrez, J. Fernandez-Ruiz, and et al. Effect of repeated systemic administration of selective inhibitors of endocannabinoid inactivation on rat brain endocannabinoid levels Biochem. Pharmacol. 70 2005 446 452
357. S. Maione, L. De Petrocellis, V. de Novellis, A.S. Moriello, S. Petrosino, E. Palazzo, and et al. Analgesic actions of N-arachidonoyl-serotonin, a fatty acid amide hydrolase inhibitor with antagonistic activity at vanilloid TRPV1 receptors Br. J. Pharmacol. 150 2007 766 781
358. A. Navarria, A. Tamburella, F.A. Iannotti, V. Micale, G. Camillieri, L. Gozzo, and et al. The dual blocker of FAAH/TRPV1 N-arachidonoylserotonin reverses the behavioral despair induced by stress in rats and modulates the HPA-axis Pharmacol. Res. 87 2014 151 159
359. B. Tan, H.B. Bradshaw, N. Rimmerman, H. Srinivasan, Y.W. Yu, J.F. Krey, and et al. Targeted lipidomics: discovery of new fatty acyl amides AAPS J 8 3 2006 E461 E465
360. L. Ducassou, G. Jonasson, L. Dhers, N. Pietrancosta, B. Ramassamy, Y. Xu-Li, and et al. Boucher JL Expression in yeast, new substrates, and construction of a first 3D model of human orphan cytochrome P450 2U1: Interpretation of substrate hydroxylation regioselectivity from docking studies Biochim Biophys Acta 1850 7 2015 1426 1437
361. D.R. Dempsey, K.A. Jeffries, R.L. Anderson, A.M. Carpenter, S. Rodriquez Opsina, and D.J. Merkler Identification of an arylalkylamine N-acyltransferase from Drosophila melanogaster that catalyzes the formation of long-chain N-acylserotonins FEBS Lett. 588 2014 594 599
362. H.B. Bradshaw, N. Rimmerman, S.S. Hu, V.M. Benton, J.M. Stuart, K. Masuda, and et al. The endocannabinoid anandamide is a precursor for the signaling lipid N-arachidonoyl glycine by two distinct pathways BMC Biochem. 10 2009 14
363. D.R. Dempsey, K.A. Jeffries, J.D. Bond, A.M. Carpenter, S. Rodriguez-Ospina, L. Breydo, and et al. Mechanistic and structural analysis of Drosophila melanogaster arylalkylamine N-acetyltransferases Biochemistry 53 2014 7777 7793
364. M. Kohno, H. Hasegawa, A. Inoue, M. Muraoka, T. Miyazaki, K. Oka, and et al. Identification of N-arachidonylglycine as the endogenous ligand for orphan G-protein-coupled receptor GPR18 Biochem. Biophys. Res. Commun. 347 2006 827 832
365. S.H. Burstein, C.A. McQuain, A.H. Ross, R.A. Salmonsen, and R.E. Zurier Resolution of inflammation by N-arachidonoylglycine J. Cell. Biochem. 112 2011 3227 3233
366. A. Cohen-Yeshurun, V. Trembovler, A. Alexandrovich, E. Ryberg, P.J. Greasley, R. Mechoulam, and et al. N-arachidonoyl-l-serine is neuroprotective after traumatic brain injury by reducing apoptosis J. Cereb. Blood Flow Metab. 31 2011 1768 1777
367. A. Cohen-Yeshurun, D. Willner, V. Trembovler, A. Alexandrovich, R. Mechoulam, E. Shohami, and et al. N-arachidonoyl-l-serine (AraS) possesses proneurogenic properties in vitro and in vivo after traumatic brain injury J. Cereb. Blood Flow Metab. 33 2013 1242 1250
368. S. Ben-Shabat, E. Fride, T. Sheskin, T. Tamiri, M.H. Rhee, Z. Vogel, and et al. An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity Eur. J. Pharmacol. 353 1998 23 31
369. S.G. Young, and R. Zechner Biochemistry and pathophysiology of intravascular and intracellular lipolysis Genes Dev. 27 2013 459 484
370. R.G. Pertwee Elevating endocannabinoid levels: pharmacological strategies and potential therapeutic applications Proc. Nutr. Soc. 73 2014 96 105
371. M. Prentki, F.M. Matschinsky, and S.R. Madiraju Metabolic signaling in fuel-induced insulin secretion Cell Metab. 18 2013 162 185
372. P.J. Kingsley, C.A. Rouzer, S. Saleh, and L.J. Marnett Simultaneous analysis of prostaglandin glyceryl esters and prostaglandins by electrospray tandem mass spectrometry Anal. Biochem. 343 2005 203 211
373. S.S. Hu, H.B. Bradshaw, J.S. Chen, B. Tan, and J.M. Walker Prostaglandin E2 glycerol ester, an endogenous COX-2 metabolite of 2-arachidonoylglycerol, induces hyperalgesia and modulates NFkappaB activity Br. J. Pharmacol. 153 2008 1538 1549
374. A. Weber, J. Ni, K.H. Ling, and et al. Formation of prostamides from anandamide in FAAH knockout mice analyzed by HPLC with tandem mass spectrometry J. Lipid Res. 45 2004 757 763
375. L. Gatta, F. Piscitelli, C. Giordano, and et al. Discovery of prostamide F2alpha and its role in inflammatory pain and dorsal horn nociceptive neuron hyperexcitability PLoS One 7 2012 e31111
376. J.K. Ritter, C. Li, M. Xia, and et al. Production and actions of the anandamide metabolite prostamide E2 in the renal medulla J. Pharmacol. Exp. Ther. 342 2012 770 779
377. N. Sang, J. Zhang, and C. Chen PGE2 glycerol ester, a COX-2 oxidative metabolite of 2-arachidonoyl glycerol, modulates inhibitory synaptic transmission in mouse hippocampal neurons J. Physiol. 572 2006 735 745
378. C.S. Nirodi, B.C. Crews, K.R. Kozak, J.D. Morrow, and L.J. Marnett The glyceryl ester of prostaglandin E2 mobilizes calcium and activates signal transduction in RAW264.7 cells Proc. Natl. Acad. Sci. U. S. A. 101 2004 1840 1845
379. N. Sang, J. Zhang, and C. Chen COX-2 oxidative metabolite of endocannabinoid 2-AG enhances excitatory glutamatergic synaptic transmission and induces neurotoxicity J. Neurochem. 102 2007 1966 1977
380. H. Yang, J. Zhang, K. Andreasson, and C. Chen COX-2 oxidative metabolism of endocannabinoids augments hippocampal synaptic plasticity Mol. Cell. Neurosci. 37 2008 682 695
381. M. Alhouayek, J. Masquelier, P.D. Cani, D.M. Lambert, and G.G. Muccioli Implication of the anti-inflammatory bioactive lipid prostaglandin D2-glycerol ester in the control of macrophage activation and inflammation by ABHD6 Proc. Natl. Acad. Sci. U. S. A. 110 2013 17558 17563
382. C. Silvestri, A. Martella, N.J. Poloso, F. Piscitelli, R. Capasso, A. Izzo, and et al. Anandamide-derived prostamide F2α negatively regulates adipogenesis J. Biol. Chem. 288 2013 23307 23321
383. S. Banni, and V. Di Marzo Effect of dietary fat on endocannabinoids and related mediators: consequences on energy homeostasis, inflammation and mood Mol. Nutr. Food Res. 54 2010 82 92
384. P.D. Cani Crosstalk between the gut microbiota and the endocannabinoid system: impact on the gut barrier function and the adipose tissue Clin. Microbiol. Infect. 18 2012 50 53
385. C. DAddario, A. Di Francesco, M. Pucci, A. Finazzi Agrò, and M. Maccarrone Epigenetic mechanisms and endocannabinoid signalling FEBS J. 280 2013 1905 1917
386. T. Bisogno, and M. Maccarrone Endocannabinoid signaling and its regulation by nutrients Biofactors 40 2014 373 380
387. K. Chen, A. Ratzliff, L. Hilgenberg, A. Gulyás, T.F. Freund, M. Smith, and et al. Long-term plasticity of endocannabinoid signaling induced by developmental febrile seizures Neuron 39 2003 599 611
388. K. Chen, A. Neu, A.L. Howard, C. Földy, J. Echegoyen, L. Hilgenberg, and et al. Prevention of plasticity of endocannabinoid signaling inhibits persistent limbic hyperexcitability caused by developmental seizures J. Neurosci. 27 2007 46 58
389. R. Kozan, M. Ayyildiz, and E. Agar The effects of intracerebroventricular AM-251, a CB1-receptor antagonist, and ACEA, a CB1-receptor agonist, on penicillin-induced epileptiform activity in rats Epilepsia 50 2009 1760 1767
390. J.J. Luszczki, P. Czuczwar, A. Cioczek-Czuczwar, and S.J. Czuczwar Arachidonyl-2′-chloroethylamide, a highly selective cannabinoid CB1 receptor agonist, enhances the anticonvulsant action of valproate in the mouse maximal electroshock-induced seizure model Eur. J. Pharmacol. 547 2006 65 74
391. G. Arslan, S.K. Alici, M. Ayyildiz, and E. Agar The role of CB1-receptors in the proconvulsant effect of leptin on penicillin-induced epileptiform activity in rats CNS Neurosci Ther 19 2013 222 228
392. H. Shafaroodi, M. Samini, L. Moezi, H. Homayoun, H. Sadeghipour, S. Tavakoli, and et al. The interaction of cannabinoids and opioids on pentylenetetrazole-induced seizure threshold in mice Neuropharmacology 47 2004 390 400
393. N. Naderi, L. Ahmad-Molaei, F. Aziz Ahari, and F. Motamedi Modulation of anticonvulsant effects of cannabinoid compounds by GABA-A receptor agonist in acute pentylenetetrazole model of seizure in rat Neurochem. Res. 36 2011 1520 1525
394. L.R. Vilela, D.C. Medeiros, G.H. Rezende, A.C. de Oliveira, M.F. Moraes, and F.A. Moreira Effects of cannabinoids and endocannabinoid hydrolysis inhibition on pentylenetetrazole-induced seizure and electroencephalographic activity in rats Epilepsy Res. 104 2013 195 202
395. S.S. Manna, and S.N. Umathe Involvement of transient receptor potential vanilloid type 1 channels in the pro-convulsant effect of anandamide in pentylenetetrazole-induced seizures Epilepsy Res. 100 2012 113 124
396. L.E. Gonzalez-Reyes, T.P. Ladas, C.C. Chiang, and D.M. Durand TRPV1 antagonist capsazepine suppresses 4-AP-induced epileptiform activity in vitro and electrographic seizures in vivo Exp. Neurol. 250 2013 321 332
397. M.J. Dowie, M.L. Howard, L.F. Nicholson, R.L. Faull, A.J. Hannan, and M. Glass Behavioural and molecular consequences of chronic cannabinoid treatment in Huntingtons disease transgenic mice Neuroscience 170 2010 324 336
398. S. Cerri, G. Levandis, G. Ambrosi, E. Montepeloso, G.F. Antoninetti, R. Franco, and et al. Neuroprotective potential of adenosine A2A and cannabinoid CB1 receptor antagonists in an animal model of Parkinson disease J. Neuropathol. Exp. Neurol. 73 2014 414 424
399. L. Song, X. Yang, Y. Ma, N. Wu, and Z. Liu The CB1 cannabinoid receptor agonist reduces L-DOPA-induced motor fluctuation and ERK1/2 phosphorylation in 6-OHDA-lesion\ed rats Drug Des. Devel. Ther. 8 2014 2173 2179
400. B.G. Ramírez, C. Blázquez, T. Gómez del Pulgar, M. Guzmán, and M.L. de Ceballos Prevention of Alzheimers disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation J. Neurosci. 25 2005 1904 1913
401. G. Fakhfouri, A. Ahmadiani, R. Rahimian, A.A. Grolla, F. Moradi, and A. Haeri WIN55212-2 attenuates amyloid-beta-induced neuroinflammation in rats through activation of cannabinoid receptors and PPAR-γ pathway Neuropharmacology 63 2012 653 666
402. E. de Lago, M. Moreno-Martet, A. Cabranes, J.A. Ramos, and J. Fernández-Ruiz Cannabinoids ameliorate disease progression in a model of multiple sclerosis in mice, acting preferentially through CB1 receptor-mediated anti-inflammatory effects Neuropharmacology 62 2012 2299 2308
403. D.A. Karanian, Q.B. Brown, A. Makriyannis, T.A. Kosten, and B.A. Bahr Dual modulation of endocannabinoid transport and fatty acid amide hydrolase protects against excitotoxicity J. Neurosci. 25 2005 7813 7820
404. M.G. Morgese, T. Cassano, V. Cuomo, and A. Giuffrida Anti-dyskinetic effects of cannabinoids in a rat model of Parkinson's disease: role of CB(1) and TRPV1 receptors Exp. Neurol. 208 2007 110 119
405. A. Bernal-Chico, M. Canedo, A. Manterola, M. Victoria Sánchez-Gómez, A. Pérez-Samartín, R. Rodríguez-Puertas, and et al. Blockade of monoacylglycerol lipase inhibits oligodendrocyte excitotoxicity and prevents demyelination in vivo Glia 63 2015 163 176